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 Cellular processes are traditionally characterized using bulk analysis. However, 
cell population averaging techniques are unable to accurately characterize these 
processes as each cell is extremely heterogeneous and can have different properties 
based on cell morphology, size, or growth phase, etc. Additionally, cell population 
averaging contains extensive sample preparation, which could alter cellular metabolites. 
Cells are sensitive to environmental perturbation (e.g. centrifugation, trypsinization, 
temperature fluctuation, etc.), so the sample preparation needed for bulk population 
analysis may skew results. 
 With advancements in instrumentation and bioanalytical tools, single cell analysis 
techniques have been increasingly characterized in the past decade.  Single cell mass 
spectrometry is a popular method for single cell analysis since high resolution mass 
spectrometers are extremely sensitive and can extract information for a broad range of 
compounds using only the volume of a single cell (i.e. a few picoliters of solution). 
Ambient mass spectrometry techniques have been utilized for single cell analysis since 
they require little to no sample preparation and can give more representative results 
about each individual cell in a near-native environment. Furthermore, live-video single 
cell mass spectrometry techniques have been developed to capture real-time analysis 
of cellular compounds from individual cells.  
 In this work, the Single-probe mass spectrometry method has been increasingly 
characterized and developed for use on a variety of cell types. The Single-probe is a 
 xv 
microscale sampling device that couples with a mass spectrometer for the real-time 
analysis of live, single cells under ambient conditions. First, the Single-probe mass 
spectrometry technique was used to detect drug compounds from individual cells 
(results not published). Then, a setup was created to allow for the analysis of 
suspension cells in solution to enable the testing of a variety of cell types from complex 
solutions. Next, the Single-probe mass spectrometry method was adapted for the first-
time quantification of mammalian cancer cell lines for adherent cells. The quantitative 
single cell analysis technique was then used to explore drug metabolism on the single-
cell level. Finally, cells derived from the urine of bladder cancer patients was tested, and 
we report the first quantification of anti-cancer compounds from single cells that were 






















Chapter 1 :  Single Cell Methods of Analysis 
 
 Traditionally, cells are characterized using bulk sampling techniques, such as the 
use of liquid chromatography mass spectrometry (LCMS) to analyze cell lysate samples. 
These bulk sampling methods require large sample volume, mask cellular heterogeneity, 
and require a lengthy sample preparation process, which could alter cellular metabolites 
and are incapable of providing real-time analysis of cells in a near-native environment.1,2 
Cell population averaging methods assume each cell is identical and will have the same 
response to environmental or chemical perturbations. However, even in a seemingly 
homogenous population of cells, cells will exhibit a heterogenous nature based on the 
rate of growth, phase in the growth cycle, and size, amongst other factors.3  
 
 
Figure 1-1. Figure of varying cell sizes and the technology the correlating technologies 






While bulk population averaging requires a large sample volume (e.g. mL’s), 
studying cells on the individual-cell level has been extremely challenging in the past due 
to the extremely complex composition and small sample volume of a single cell (~ a few 
picoliters for a single mammalian cancer cell). The majority of single cell analysis 
techniques were developed on relatively larger cells (e.g. plant cells or embryos) (Figure 
1-1).5 However, in the past decade, advancements in instrumentation have made single-
cell analysis (SCA) feasible using a variety of bioanalytical techniques. In this work, we 
will explore the various single cell analysis techniques, with an emphasis on single cell 
mass spectrometry as that is the technique explored in the upcoming chapters and is one 
of the most widely-used techniques for single cell analysis high resolution mass 
spectrometers are capable of extracting information from a variety of compounds 
simultaneously from a small sampling volume.  
1.1 Bioanalytical Techniques for Single Cell Analysis 
 Single cell analysis techniques can be grouped by which part of the cell is being 
studied. For example, DNA sequencing and microarrays are traditionally used for the 
study of genes (i.e., epigenomics and genomics) and transcriptomics at the single-cell 
level. Mass spectrometry (MS) and protein arrays are used for proteomics, and single-
cell metabolomics is characterized using MS and nuclear magnetic resonance (NMR).6 
Other techniques for SCA include microfluidics, spectroscopy, and flow cytometry. As 
technology advances, the sensitivity and selectivity of each method is improving to give 





1.1.1 DNA Sequencing. 
DNA sequencing on the single-cell level has important implications in the 
biomedical community since genes associated with diseases, such as cancer or 
hereditary illnesses, can be discovered for earlier treatment.7 These techniques often 
stem from Sanger sequencing, first implemented in 1977 for the determination of a 
bacteriophage genome. Sanger sequencing creates multiple copies of the sequenced 
region, up to ~900 base pairs, by combining the sample with primer, DNA polymerase, 
and labeled nucleotides in a test tube, heating the mixture to denature the DNA strand, 
and cooling the newly-created single-stranded DNA so that the primer can bind to it. Once 
the primer is bound, the mixture is again heated so DNA polymerase can use the primer 
to incorporate nucleotides until one of the labeled nucleotides is added, which will create 
a fluorescent base. This process of denaturing, annealing, and extending DNA is known 
as polymerase chain reaction (PCR).8 Repeating this cycle ensures that the labeled 
nucleotides are incorporated into the DNA fragments, and each fragment will have 
different lengths, ending at the DNA sample initially added into the test tube. Capillary gel 
electrophoresis can be used to analyze the fragments of different masses since larger 
masses will move more slowly than smaller fragments, and a fluorescence detector can 
be used to determine which nucleotide was incorporated into each individual fragment.9,10 
Genomic DNA from individual eukaryotic cells was first sequenced in 1999 using 
fluorescently-labeled cells to ensure only one cell was pipetted from the original bone 
marrow sample, followed by amplification using polymerase chain reaction (PCR) and 
fluorescence detection to describe regions of the DNA responsible for cancer.11 DNA 




was first achieved by Turner et al in 2009.12 Instead of using the traditionally-used 
fluorescent nucleotides that have difficulty incorporating into consecutive positions, which 
makes real-time analysis impractical, Turner et al utilize a fluorophore that phospholinked 
into the DNA terminus. The group also adds a zero-mode waveguide nanostructures to 
aid incorporation by minimizing the volume of observation, which allows for higher 
concentrations of labeled nucleotides to be used, speeding up the reaction.12 DNA 
sequencing at the single-cell level can provide useful information of genetic variants and 
gene evolution.  
1.1.2 Flow Cytometry and Microarrays for SCA. 
Flow cytometry is another biochemical method of analysis that involves 
fluorescence. The sample is exposed to a laser, enabling a readout based on the way in 
which each cell reflects the light. This technique can be used to separate cells based on 
their heterogenic properties.13 Since cellular heterogeneity is a main consideration for 
SCA techniques, this method is extremely important. It can also be used in conjunction 
with other techniques to explore heterogeneity at the single-cell level, using MS instead 
of a fluorescence detector.14  
A pitfall of flow cytometry is the inability to monitor states before and after laser 
stimulation, which could alter cellular properties. In addition, the flow cytometer creates 
significant background noise that could interfere with analyte. To combat these issues, 
microarrays were introduced in 2005 to measure the amount of intracellular calcium 
(Ca2+), an important part of the signaling pathway. The polystyrene microarray chip was 
fabricated to include over 200,000 microchambers 10 µm wide, 12 µm deep, and 30 µm 




one cell. The fluorescence of each cell was recorded using a microarray scanner, creating 
a high throughput method for the analysis of many different individual cells 
simultaneously.15 Microarrays have been utilized for the single cell analysis of both 
mammalian and plant cells.4,6,16,17 
1.1.3. Raman Spectroscopy. 
 Raman spectroscopy has high spatial resolution (< 1 µm) and does not require 
any labeling, so it is a good technique for the visualization of cells.18 Additionally, 
minimal sample preparation is required since this technique is based on the 
measurement of photons emitted from samples due to Raman scattering of a light 
source, such as a laser.19 Raman spectroscopy has been utilized to characterize the 
phase in the cell cycle from individual cells or discriminate amongst cell types.20  Since 
this method can distinguish between different types of cells, it may be helpful in the 
future for sorting patient-derived cells. This technique can also be used to study drug-
cell interactions since the Raman band intensities will change after the cell is treated.21  
However, current Raman spectroscopy-based single cell measurement methods are not 
compatible with suspension cells, so cells must be attached to substrates. This sample 
preparation could change the Raman spectra and give misleading information about the 
cell.  
1.1.4. Microfluidics. 
 Microfluidics are being increasingly characterized for single cell analysis 
techniques as the channels are often similar in size to a single cell (~10 µm in diameter) 




coupled with various detection techniques for cell analysis. In 2011, Dochow et al. 
combined microfluidics with Raman spectroscopy to classify various tumor cells.23 This 
could be beneficial to studies in both areas of research since the microfluidic chip allows 
for the analysis of cells in solution and Raman spectroscopy allows for the analysis of 
unlabeled compounds. A large number of microfluidic applications on the single cell 
level have been reported, including the correlation of heavier cells with faster growth 
rates and characterization of gene or protein expression.24–30 Although many different 
detection techniques can be potentially integrated with microchips, a downfall to 
microfluidic techniques is that they are traditionally coupled to fluorescence detectors, 
limiting the amount of information that can be obtained simultaneously and requiring 
labeled samples.31 However, microfluidic chips can be further developed in conjunction 
with mass spectrometry to give more molecular information about cellular content in a 
label-free manner.  
 
1.2 Single Cell Mass Spectrometry Techniques 
 Single cell mass spectrometry (SCMS) approaches are being increasingly 
characterized for their ability to identify a wide range of compounds simultaneously in a 
label-free manner. In general, mass spectrometry (MS) experiments utilize an ionization 
method (e.g., matrix assisted laser desorption/ionization (MALDI), laser, electrospray 
ionization (ESI), and electron ionization (EI)), a mass analyzer (e.g., quadruple, time-of-
flight (TOF), Fourier-transform ion cyclotron resonance (FT-ICR), and Orbitrap) to filter 
out neutral species and separate compounds based on their mass-to-charge ratio, and a 




measurement of image current). MS continuously scans a wide mass range, and it utilizes 
a compound’s mass-to-charge ratio to determine its identity.  
SCMS methods can be broadly grouped, based on their sampling and ionization 
environment, into non-ambient (vacuum-based) or ambient techniques. Non-ambient 
techniques, such as matrix-assisted laser desorption ionization (MALDI) and time-of-flight 
secondary ion mass spectrometry (TOF-SIMS), require a vacuum environment for 
sampling and ionization. For example, MALDI has been used to profile molecular 
components from a variety of single cells, including bacterial cells, frog embryos, plant 
cells, and mammalian cells.32–38 Vacuum-based techniques have been used to 
revolutionize the ‘-omics’ studies, especially peptidomics, proteomics, lipidomics, and 
metabolomics.2,6,39–45  These methods have high detection sensitivities, but they also 
require sample pretreatment, making these methods incapable of real-time analysis or 
analysis of live cells from a native environment.  
 Ambient MS methods have been adapted for the analysis of samples in a near-
native environment. Ambient techniques can be broadly grouped into microprobe 
extraction and laser desorption/ionization methods. Microprobe extraction techniques 
may either use a large probe that encapsulates the cell before being lysed for analysis or 
use a smaller probe that penetrates the cell membrane and extracts information from the 
inside. They have been used for the analysis on a variety of cell types, including frog 
embryos, onions, stem cells, and mammalian cancer cells.31,46–59 Extraction methods 
stem from live-video single cell mass spectrometry developed by Masujima’s group.58 
Laser desorption/ionization methods have primarily been used to study embryos, but 




Additionally, there have been other ambient techniques created for the analysis of cellular 
compounds at the single-cell level, including separation techniques (e.g. capillary 
electrophoresis (CE)) or ion mobility mass spectrometry.60,77–79 
1.3  Single-probe Mass Spectrometry 
The Single-probe MS technique is an ambient technique that falls under the 
microprobe extraction category and is most similar to live-video mass spectrometry. The 
Single-probe is a microscale sampling and ionization device that can be coupled to a 
mass spectrometer for studies in multiple research areas. It consists of dual-bore quartz 
tubing that is transformed into a sharp tip (<10 µm in diameter-similar to the size of an 
individual cell) using a laser puller. A capillary is placed into each bore: one that will 
connect to a conductive union and one that is flame-pulled to function as a nano-ESI 
emitter. The other side of the conductive union is connected to a longer capillary that 
connects the probe to the sampling syringe. To be conveniently used in the experiment, 
the Single-probe is attached to a glass slide and secured into a flexible arm clamp on a 
home-built stage for analysis. The dual-bore probe allows for real-time analysis of 
intracellular metabolites and drug compounds. As solvent flows through the tip, a liquid 
junction is formed. Cellular contents are extracted towards the nano-ESI emitter through 
a self-aspiration process and then ionized for MS analysis. Two digital microscopes are 
used to monitor the position of the nano-ESI emitter and cell penetration by the Single-
probe tip.46 
The Single-probe MS technique has been modified and utilized for multiple 
applications, including MS imaging (MSI) to map the spatial distributions of molecules 




of intracellular compounds from algal and adherent mammalian cells.46,48,80–88 In later 
chapters of this work, we expand the Single-probe MS technique to include the analysis 
of non-adherent cancer cell lines and quantification of drug compounds from individual 
cells, including non-adherent cells and cells derived from the urine of bladder cancer 
patients.89,90 
1.4 Quantitative Single Cell Mass Spectrometry (qSCMS) 
 The quantification of molecules on the single-cell level has the potential to 
enhance our knowledge of biochemical processes or pathways, drug efficacy, or 
metabolism and revolutionize the standard of care by creating more individualized 
treatment plans. While there have been a number of qualitative SCMS techniques 
developed, quantitative MS measurements at the single-cell level is a relatively new 
field.  
 Quantification of single cells began with semi-quantitative techniques before 
progressing onto quantitative methods of analysis. These semi-quantitative techniques 
compare ratios of an internal standard to see how a compound has changed (i.e. 
increased or decreased) upon treatment.91–95 To date, there are very few reports of 
absolute quantifications of molecules;66,96,97 however, in chapters 4-6, we report the 
absolute quantification of drug compounds from individual mammalian cancer cell lines.  
1.5 Future Perspectives 
 Single cell analysis techniques are continually being developed to enhance our 
understanding of cellular processes since we know studying disease states begins 




tumors, some tumors may even contain different types of cells, such as cancerous and 
healthy cells in their masses. Therefore, single cell analysis methods are needed to fully 
conceptualize these mechanisms of action. As these methods are becoming 
commercialized, we are learning more about biochemical processes, including drug 
metabolism, drug-drug interactions, and drug-cell interactions. While there is still a large 
gap in knowledge, single cell analysis techniques are providing more accurate information 


















Chapter 2 :  Integrated Cell Manipulation Platform Coupled with 
the Single-probe from Mass Spectrometry Analysis of Drugs 
and Metabolites in Single Suspension Cells 
 
2.1 Introduction 
Human biology, especially disease biology, is increasingly understood to be the 
result of activities on the level of individual cells, but the traditional analytical methods, 
such as liquid chromatography mass spectrometry (LCMS), are generally used to analyze 
samples prepared from populations of cells, whereas the acquired molecular information 
cannot accurately represent the chemical processes on the individual-cell level. These 
standard, traditional methods are unable to discern the effects of cellular heterogeneity 
on an analytical measurement, and the process of destroying and mixing the cells to 
prepare the lysate potentially leads to the alteration or loss of cellular components.2,98 
These limitations of traditional methods are especially important in the analysis of patient 
cells, in which the obtained samples can contain a complex mixture of many different cell 
types. To overcome these deficiencies, single cell molecular analysis methods, including 
single cell mass spectrometry (SCMS) methods, are increasingly being developed and 
applied to bioanalysis, especially of cellular metabolites and low molecular weight 
biomolecules.42,99  
The first SCMS techniques developed use vacuum-based techniques to perform 
the analyses under non-ambient conditions.2,39,43,100–104  Non-ambient SCMS techniques 
are capable of analyzing cellular lipids and metabolites, but require sample pretreatment 
under artificial conditions, and therefore are not suitable for real-time analysis. The 




components, and this preparation can alter cellular components from their natural 
environment.69 Therefore, ambient mass spectrometry (MS) techniques, which do not 
require a vacuum for the sampling environment, are utilized to analyze cells in a near-
native environment. Not having a vacuum environment allows for versatility in the 
experimental design; cameras can be added to monitor the cellular process and softer 
ionization techniques can be combined with separation techniques to receive better 
information from each single-cell experiment.31,42,46,47,49,52–61,63,64,67–74,77–79,105–108 
The Single-probe SCMS method is an ambient technique that analyzes live, 
mammalian cancer cell lines in a near-native environment.46,84,87,90,109 In addition, the 
Single-probe device has been used for other  mass spectrometry applications, including 
analysis of extracellular molecules in multicellular spheroids and MS imaging of 
tissues.48,80,82,83,85,86 However, since cell immobilization on substrates is required for this 
method, suspension cells cannot be directly analyzed using this technique.99,110 
Therefore, the Single-probe SCMS system could not be directly used to sample non-
adherent single cells, such as non-adherent cell lines or suspension cells isolated from a 
patient’s blood or other bodily fluids.111  
In this work, an integrated cell manipulation platform (ICMP) is coupled with the 
Single-probe SCMS technique to analyze live, suspension cells on-line with minimal 
sample preparation (Figure 2-1).90 The ICMP consists of an inverted microscope to 
monitor cell selection, a glass cell-selection probe, a microinjector to capture individual 
floating cells, a heated plate to maintain cellular temperature, two cell manipulation 
systems to control spatial movements of both the glass cell-selection probe and Single-




to the Single-probe tip. The fabrication of the Single-probe is detailed in previous 
publications and will not be addressed here.46,48 The ICMP/Single-probe system is 
coupled to a high resolution mass spectrometer. This integrated setup allows for the 
sampling of identified single cells from complex biological samples with minimal effects 
from matrix molecules.   
2.2 Methods 
2.2.1. Glass Cell-Selection Probe Fabrication 
Convert single-bore glass tubing into a tapered probe with a sharp tip. Place a 
single-bore glass tube (ID: 0.3 mm, OD: 1.1. mm) into the clamps of a vertical pipette 
holder, centering the glass with respect to the heating coil and tighten to secure the tube 
in place. (The heating coil is comprised of an 18-gauge nickel-chromium resistance wire 
(~60 mm in length) coiled around a metal rod (diameter = 3.90 mm) 2.5 times.) Set the 
glass tubing with temperature program 19.5 (manufacturer’s unit). Set the solenoid 
plunger at 4 (manufacturer’s unit) and trigger the solenoid to pull the glass tubing. This 
step creates two probes fused at the tip. Use tweezers to cut ~1 mm away from the tip of 
each probe, creating an orifice of ~10 µm in diameter at the probe tip.  
Bend the glass probe for easy coupling to the ICMP/Single-probe SCMS setup. 
Set a pulled glass probe into the microforge, positioning the tip ~3 mm above the platinum 
heating wire. Turn the heat on the platinum wire to 30% of the maximum temperature and 






Figure 2-1. Experimental setup for the single suspension cell MS experiments. (A) The 
integrated cell manipulation platform (ICMP) coupled with a mass spectrometer. (B) 
Schematic for analysis of suspended cells. (C) Experimental view of K562 cells to be 
selected using the cell-selection probe. Reprinted with permission from Standke et al.90 




2.2.1 Integrated Cell Manipulation Platform Assembly 
Place the inverted microscope, microinjector, and two cell manipulation systems 
on a motorized table for easy coupling with the mass spectrometer. Modify one of the cell 
manipulation systems to accommodate a Single-probe by replacing the end with an arm 
clamp. Use a plastic syringe with a needle to fill the microinjector with mineral oil. Avoid 
bubbles in the tubing as this will affect suctioning. Replace the stage insert of the inverted 
microscope with the heated plate. Set the heated plate at 37C prior to analysis. 
2.2.2 Set up the glass cell-selection device. 
Insert the glass cell-selection probe inside the metal holder of the microinjector by 
placing the long (non-bent) side into the capillary holder and tightening the screw to 
secure the probe in place. Position the probe tip’s angle parallel to the heated plate.  
CAUTION: The glass probe is very sharp and fragile, and it breaks easily. Protect your 
eyes and be extra cautious while inserting the probe into the microinjector. Secure the 
metal holder of the microinjector into the cell manipulation system. Position the probe tip 
near the middle of the inverted microscope light.  
2.2.3. Create an Extended Ion Transfer Tube for the Mass Spectrometer Inlet 
Use a metal cutter to cut a piece of stainless-steel tubing (OD: 0.0625 (1/16) in, 
ID: 0.021 in) ~250 mm in length. Measure 135 mm from the end and place a metal feral 
so ~135 mm will be exposed to the atmosphere and ~115 mm will be inside the mass 




2.2.4. Couple the ICMP with Single-probe Setup 
Secure the glass slide containing the Single-probe into the arm clamp of the cell 
manipulation system. NOTE: Single-probes are fabricated according to a previously-
published protocol48 with two minor changes in the current study: the nano-ESI emitter is 
made longer for easy coupling to the mass spectrometer, and the Single-probes are glued 
to the glass side on the right-hand side to avoid interfering with the spatial movement of 
the glass cell-selection device (Figure 2-2). Connect the solvent-providing capillary to a 
conductive union by placing the capillary into the sleeve (1/16 x .005 in) of the plastic 
ferrule and finger-tightening the fitting. Connect the other side of the conductive union to 
a capillary (ID: 40 µm, OD: 150 µm), which is connected to a syringe containing the 
sampling solvent, by placing the capillary into the sleeve (1/32 x .007 in) and tightening 
the fitting. Acetonitrile with 0.1% formic acid is utilized as the sampling solvent in these 
experiments. NOTE: The sampling solvent is flexible, but it should primarily contain 
acetonitrile (or acetonitrile with formic acid for better ionization) for a rapid microscale cell 
lysis. 
Secure the syringe into the syringe pump on the mass spectrometer and place the 
ionization voltage cord onto a copper wire attached to the conductive union. Then, 
position the nano-ESI emitter ~ 1mm to the orifice of the extended ion transfer tube. Use 
the cell manipulation system to control the spatial movements of the Single-probe and 






Figure 2-2. Photo of a modified Singe-probe and a cell-selection probe utilized for single 
suspension cell MS experiments. 
 
2.2.5. Suspended Cell Sample Preparation 
The day before analysis (~18-24 h), seed out cells for testing in a cell culture flask 
(T25). K562 human myeloid leukemia cells are used as models in this study. Heat 1X 
phosphate buffered saline (PBS) and Roswell Park Memorial Institute (RPMI) medium 
supplemented with 10% synthetic fetal bovine serum (FBS) and 1% penicillin-
streptomycin at 37°C for 30 min. Seed out ~1x106 cells in a total volume of 10 mL by 
combining cells with warm medium. In general, use a 10-mL pipette to place 8 mL of 
RPMI medium into a cell culture flask. Then, use a 2-mL pipette to put 2 mL of confluent 
K562 cells the medium for ~1x106 cells. Incubate the cells at 37°C and 5% CO2 until 
analysis.  
Prepare cells for analysis. Pipette cells from the cell culture flask into a 15-mL 
centrifuge tube. Spin cells down at 400 x g and 37°C for 5 min and discard the 




the desired treatment concentration. NOTE: For analysis of control cells, resuspend the 
cells in 4 mL of RPMI medium or PBS and place into the lid of a small Petri dish for 
analysis. Incubate the cells for the duration of the treatment time at 37°C and 5% CO2. 
Spin cells down at 400 x g and 37°C for 5 min. Aspirate the supernatant. Cells are 
resuspended in 10 mL of PBS, and centrifuged at 400 x g and 37°C for 5 min. After 
spinning, discard the supernatant. Repeat this step 3 times to minimize detection of drug 
from extracellular constituents. Resuspend cells in 4 mL of PBS for analysis. 
2.2.6. Perform SCMS Measurements using the ICMP/Single-probe Setup 
Customize parameters for the mass spectrometer for the experiment. Under the 
Scan Mode heading of the instrument software, select “Define Scan.” Use a resolution of 
60,000 m/∆m at m/z 400, 1 microscan, 100 ms maximum injection time, and automatic 
gain control (AGC) on. A mass range (m/z) of 100-1000 was utilized for the experiments. 
NOTE: Parameters can be modified based on the instrument model. Under Syringe 
Pump, select a flow rate of 150 nL/min. NOTE: Flow rate needs to be optimized for each 
experiment. Select NSI Source and apply a voltage of ~4.5 kV.  
NOTE: This parameter also needs to be optimized for each experiment.  
 Prepare the ICMP for analysis. Turn on the inverted microscope (with 40X 
magnification selected for both the top plate and bottom lens) and connect it to the USB-
port of a laptop to capture live-video feeds. Turn on the heated plate and set it to 37C. 





Prepare sample for analysis. Pipette 2-3 mL of sample into the lid of a small Petri 
dish (35x12 mm), positioning the sample in the center of the light from the inverted 
microscope on top of the heated plate.  
Prepare the glass cell-selection probe for analysis. Use the cell manipulation 
system to move the probe so its tip is focused under the inverted microscope in the same 
plane as the cells.  
Select an individual cell for analysis. Use the cell manipulation system to move the 
cell-selection probe tip to a targeted cell. This process is monitored using the inverted 
microscope. NOTE: If the tip of the cell-selection probe cannot be focused in the same 
plane as the cells, it is possible that the bent part of the probe is not appropriately angled, 
so adjust the position of the cell-selection probe until both probe tips can be focused along 
with cells under the microscope.  
Gently turn the handle of the microinjector to adjust the position of the mineral oil 
inside the tubing. A gentle suction is provided by the microinjector to secure the targeted 
cell to the cell-selection probe tip. NOTE: If the cell cannot be captured by the cell-
selection probe through the suction force, check the cell-selection probe to ensure it is 
fully-inserted into the capillary holder. In addition, inspect the mineral oil levels in the 
microinjector and tubing, and expel air if there is any. 
Use the cell manipulation system to move the cell at the cell-selection probe tip to 
the Single-probe tip, using a digital microscope focused on the Singe-probe tip to monitor 
this process. When touching, a small acetonitrile droplet at the Single-probe tip induces 
a rapid lyses of the cell, and then cell lysate is immediately ionized for on-line MS analysis. 




gentle suction, this cell can be potentially detached during its transfer to the Single-probe 
tip. Therefore, if ion signals of typical cellular lipids (see Representative Results) are not 
observed within 5 s, it is possible that the cell became unattached, and the selection of a 
different cell is needed.  
2.3. Representative Results 
First, untreated K562 cells are used to establish the experimental method. In a 
typical SCMS experiment, obvious changes of mass spectra can be observed from 
transferring a cell, during the detection of cellular contents, and after finishing the 
measurement (Figure 2-4). Three common cellular lipid peaks (phosphatidylcholine, PC), 
including PC(34:4) (m/z 754.536), PC(36:4) (m/z 782.567), and PC(38:5) (m/z 808.583), 
are monitored to ensure the cell is successfully transferred and cellular contents are 
detected46,84,90,112,113 (Figure 3-3). If lipid peaks are not seen within 5 s, the mineral oil 
level in the microinjector is altered to reduce the suction holding the cell at the cell-
selection probe tip; caution needs to be taken so that no mineral oil is pushed out from 
the cell-selection probe. The identity of many PC’s in the mass range of m/z 750-850 are 
confirmed using MS/MS on untreated cell lysate samples (Figure 3-1, Figures A1, A2, 












Table 2-1. Identified cellular components using the ICMP/Single-probe setup. 
Drug Molecule* m/z Mass Error (ppm) 
[Gemcitabine + H]+ 264.0760 11.32 
[Taxol + Na]+ 876.3183 2.74 
[OSW-1 + Na]+ 895.4448 0.89 
 
Cellular Lipids m/z Mass Error (ppm) 
[PC(34:4) + H]+ 754.5353 3.71 
[PC(34:3) + H]+ 756.5512 3.44 
[PC(34:2) + H]+ 758.5689 0.66 
[PC(36:5) + H]+ 780.5514 3.07 
[PC(36:4) + H]+ 782.5677 2.17 
[PC(36:3) + H]+ 784.5846 0.64 
[PC(38:7) + H]+ 804.5505 4.10 
[PC(38:6) + H]+ 806.5674 2.48 
[PC(38:5) + H]+ 808.5829 2.72 
[PC(38:4) + H]+ 810.6007 0.00 
[PC(40:7) + H]+ 832.5825 3.12 
 
*The detection of all drug compounds was confirmed by comparing the MS/MS results 
with the standard compound. 
 
K562 cells are also subjected to treatment with various drug compounds to expand 
the versatility of the method. K562 cells are incubated with gemcitabine (1 µM) and taxol 
(1 µM) for 1 h and OSW-1 (100 nM, 1 µM) for 4 h and 2 h, respectively. Cells are then 
washed with PBS to minimize the detection of drug compounds from extracellular content. 
The contribution of matrix (e.g. ions from cell culture medium, PBS, and solvent) to mass 
spectra of cellular contents can be eliminated through data subtraction, due to their 
significantly different ion signals (Figure 2-3).  All three drug compounds are detected 
using the ICMP/Single-probe MS setup (Figure 3-4).90 These results suggest this method 
can be used to study intracellular lipids, drugs, and metabolites on the single-cell level 





Figure 2-3. Mass spectra of (A) RPMI cell culture medium, (B) PBS, and (C) an individual 
K562 cell. (D) A zoomed-in region (m/z 750-760) of the combined three spectra (manually 
combined) from an individual K562 cell, RPMI media, and PBS showing the differences 
among them, indicating the identified PC species (highlighted) from the cell can be clearly 
distinguished. 
 
2.4 Discussion of Results 
The integrated cell manipulation and analysis platform is constructed to expand 
the versatility of the Single-probe MS method, allowing for on-line, rapid analysis of non-
adherent cells in a near-native environment. A major advantage of the technique is that 
minimal sample preparation is required, so the cells are analyzed in conditions that mimic 
their standard state. Particularly, individual cells of interest can be visually identified and 
selected, minimizing the influence of matrix effect on MS ionization efficiency while 
maintaining cells in their natural environment, so the results are more representative cells’ 






Figure 2-4. The zoomed-in mass spectra (m/z 500-1000) showing changes of ion signals 
(A) before analysis of a cell, (B) during acquisition of the cell, and (C) after cell analysis 






This technique can be potentially used to study patient cells suspended in biofluids 
in future studies. Another advantage of this technique is the flexible selection of the 
sampling solvent. It is important to include acetonitrile as the main sampling solvent so 
that microscale lysis can occur rapidly.  Potentially, internal standards (e.g. isotopically-
labeled drug compounds) can be added into the sampling solvent for quantification of 
molecules of interest (e.g. drug molecules) from individual cells, including those can play 
a key role in revolutionizing personalizing drug treatments in the future.111   
Although this integrated system can be conveniently used to analyze broad ranges 
of cells, a limitation of the method is that neither the Single-probe nor cell-selection probe 
is commercially-available; dictating the need for optimization of many parameters (e.g. 
flow rate, voltage, length between the nano-ESI emitter and ion transfer tubing, etc.) prior 
to each experiment. In addition, due to the smallness of the Single-probe and cell-
selection probe, environmental perturbation (e.g. air flow) may result in difficulties 
establishing a junction between the two probes. A short-term solution is the bending of 
the cell-selection probe close to the end to minimize the length of tapering. Future work 
includes the development of a housing to enclose the critical parts of the setup to minimize 
environmental effects. Due to the limited amount of cellular contents and short acquisition 
time (~2-3 s) from a cell, MS/MS analysis can be only conducted for relatively abundant 
species. Other factors influencing the detection sensitivity include the suppressed 
ionization efficiency due to the introduction of matrix along with the cell and potential ion 
loss through the extended ion transfer tubing.  






Chapter 3 :  Mass Spectrometry Measurement of Single 
Suspended Cells using Combined Cell Manipulation System 
and the Single-probe Device 
3.1 Introduction 
 Liquid biopsy samples from patients, such as blood plasma, saliva, urine, or fine 
needle aspiration, are a complex milieu of different types of individual cells, and therefore 
any bioanalysis of the multi-cellular patient sample would likely be extremely 
heterogenous.114 Moreover, patient-derived cells are typically converted into lysate and 
then analyzed using a bulk sampling technique, such as liquid chromatography mass 
spectrometry (LCMS). However, bulk analysis masks cellular heterogeneity, and the 
cellular characteristics, metabolites, and responses to drug administration in an abnormal 
subpopulation would be mixed with signals from healthy cells.14,115 A better approach 
would be to focus the bioanalysis on the individual patient cells levels, but the limited 
volume of an individual cell (i.e., ~1-3 picoliters),5 along with spectral interferences from 
sampling medium, make analysis on the single-cell level extremely challenging. 
Additionally, many cellular bioanalytical methods, including some single cell methods, 
require complex sample preparation prior to measurement.116 Extensive sample 
preparation, including cell attachment and detachment, centrifugation, and changes to 
the cellular environment can alter cellular metabolites and morphologies.98 Therefore, a 
rapid, real-time analysis is necessary to study cells in a near-native state.14,115 
Advancements in instrumentation over the past decade have allowed single cell analysis 




unable to be accounted for using bulk sampling techniques. Current methods of SCA 
include flow cytometry,4,6,16,17 microfluidics,25,31 RNA sequencing,117,118 and mass 
spectrometry (MS) methods of analysis.2,4,99,119  
    Single cell mass spectrometry (SCMS) is becoming popular due to its label-free 
approach and ability to detect broad ranges of analytes, including lipids, peptides, and 
metabolites.69,99  SCMS can be characterized into two groups, ambient and non-ambient 
analysis, according to their sampling and ionization environment. Non-ambient 
techniques are vacuum-based and require sample pretreatment, while ambient 
techniques are often performed in a near-native environment with minimal sample 
preparation. A pitfall of non-ambient SCMS techniques is the inability to study live cells in 
real time in normal cellular environments. Changes to the cellular environment could alter 
cellular metabolites. Thus, a number of ambient SCMS techniques have been developed 
for the measurement of live mammalian cells. These techniques analyze cellular contents 
obtained from individual cells using micro-probe extraction31,46–48,50–59,108,109,120 or laser 
desorption/ionization.60–66,68,69,71–75,121 Among these ambient SCMS techniques, the 
Single-probe SCMS technique allows for real-time, in situ analysis of live cells, including 
mammalian and plant cells.82,83,87,122–125 Microscale separation methods, such as capillary 
electrophoresis (CE), and post-ionization methods, such as ion mobility (IM)99 have been 
coupled to MS to minimize spectral interferences during single cell analysis.78,79 A 
prerequisite of many non-ambient SCMS techniques is the need for an immobilized 
substrate to secure cells, such as preparing a frozen, hydrated sample or utilizing 
micropatterned poly stencil film.99 Because cellular metabolites are sensitive to the 




medium, may potentially affect the molecular composition inside cells. A bioanalytical 
method capable of rapidly measuring drug pharmacology on single cells isolated from 
patients under ambient conditions could be used to develop personalized drug 
therapeutic regimens tailored to the individual’s response to a drug.110 
    SCMS techniques are often limited by the amount of content available from an 
individual cell. Single cells have a much smaller sample volume than bulk samples used 
in traditional analytical techniques, but still maintain extremely complex compositions 
without extensive sample pretreatment. For example, typical cultured mammalian cells 
contain only a few picoliters of solution (individual cell size ~10-20 µm in diameter), but it 
is estimated that more than 109 proteins and 1010 lipids are present in one single cell.42 
Limited amount and complex composition of cellular contents from individual cells lead to 
challenges generally present in SCMS studies, particularly for cancer cells with small 
sizes (e.g., ~10-13 µm).54,70,106,126–130  
    Despite the small sampling size of cultured cells, the Single-probe SCMS technique 
has demonstrated its success qualitatively with metabolic profiling in individual 
mammalian cancer cell lines. In addition, this technique has been used for other 
applications, including MS tissue imaging28,30 and analysis of extracellular molecules 
inside live multicellular spheroids.56,57 There are a number of advantageous features 
unique to the Single-probe SCMS technique, including versatile selection and 
composition of the sampling solvent, capabilities for real-time and in situ analysis, and 
potential compatibility with broad types of mass spectrometers. However, this technique 





    In this work, we report the development of an integrated cell manipulation platform 
(ICMP), which combines the Single-probe SCMS method with a single cell manipulation 
platform, to analyze individual, suspended cancer cells in real time in a near-native 
environment with minimal sample pretreatment. This new instrumental setup allows for 
the direct selection and analysis of individual cells present in their original complex 
matrices. Because matrix molecules in the sample solution are generally eliminated upon 
analysis, the matrix effect, which results in reduced ionization efficiency and detection 
sensitivity, is minimized.  While Chapter 2 focused on the methodology behind the ICMP, 
this chapter focuses on the versatility of the method and the potential impact that 
analyzing a variety of cell types from solution can have for various disease states in the 
future. 
3.2 Experimental Setup 
    To conduct SCMS of suspended cells, this ICMP setup is coupled to a high-resolution 
Thermo LTQ Orbitrap XL mass spectrometer, and a Single-probe is used as the sampling 
and ionization device. This multifunctional cell manipulation system (Figure 2-1) consists 
of two Eppendorf TransferMan cell micromanipulation devices (to control spatial 
movements of both the glass cell-selection device and Single-probe), a Nikon Eclipse 
TE300 inverted microscope (for cell monitoring), and a Tokai Hit ThermoPlate system (to 
mimic the temperature of the cells’ natural environment). A cell-selection probe, which is 
a glass tubing with a small tip size, is connected to a microinjector, which is coupled with 
one of the Eppendorf manipulation systems to capture target cells. The other Eppendorf 
manipulation system is modified to allow a Single-probe interface with the mass 




one. Cells are randomly selected with the cell-selection device using a digital 
stereomicroscope, and then transferred to the Single-probe tip for real-time microscale 
lysis followed by MS analysis (Figure 3-1).  
 
 
Figure 3-1. Transferring a live single cell from the cell-selection probe tip to the Single-
probe tip. Solvent (acetonitrile) droplet created between the Single-probe and cell-
selection probe induces a rapid microscale lysis of the cell followed by MS analysis. 
Reprinted with permission from Standke et al.90 Copyright 2019 American Chemical 
Society. 
 
3.2.1 Fabrication of the cell-selection probe 
A single-bore glass tubing (ID: 0.3 mm, OD: 1.1 mm, RSC, Rochester, NY) was 
tapered to act as a cell-selection device (with a tip size ~15 µm) using a vertical pipette 
puller (KOPF, Tujunga, CA). To adapt this glass needle for the suspended cell setup, its 





3.2.2. Single-probe fabrication 
Single-probes were fabricated using a previously published protocol, so only a 
brief summary will be given here.46 Dual-bore quartz tubing (Friedrich & Dimmock, 
Millville, NJ; OD: 500 µm, ID: 127 µm) was pulled into a sharp needle (OD ~ 5 µm) 
using a micropipette laser puller (Sutter, Novato, CA). Fused silica capillary (OD: 110, 
ID: 40 um) was inserted into one bore to act as a solvent-providing capillary. The same 
diameter capillary was flame-pulled and inserted into the other channel of the dual-bore 
quartz needle to act as a nano-ESI emitter. The probe was sealed using UV resin 
(Prime-Dent, Chicago, IL) and secured on a glass slide with Epoxy glue (Devcon, 
Hartford, CT) for easy coupling to the flexible arm clamp. 
3.2.3. Sample preparation 
 For suspended cell experiments, K562 cells were utilized. K562 cells (ATCC, 
Manassas, VA) are derived from chronic myeloid leukemia. This cell line was chosen for 
its non-adherent culture conditions and relatively large size (~15-20 µm diameter) 
among all cancer cell lines.131 K562 cells were maintained in T25 flasks at 37C and 5% 
CO2 in RPMI media supplemented with 10% FBS and 1% penicillin-streptomycin. Cells 
were seeded out at 5.0e5 cells per flask 24 hr prior to treatment and transferred to a 12-
mL centrifuge tube for treatment with various drug compounds, including taxol, 
gemcitabine, and OSW-1. Prior to analysis, cells were pelleted at 500 RCF for 5 
minutes at 37C and washed with 10 ml of PBS (x3) to avoid detection of the drug 
compound from extracellular content. K562 cells were then resuspended with PBS (4 




 For metabolomic analysis, K562 cells were seeded at 5.0e5 cells per flask 24 
hours prior to treatment. 100-nM Taxol was added to one flask and left to incubate for 
24 hours. Following the incubation, cells were directly analyzed using the integrated cell 
manipulation platform.  A minimum of 22 cells were analyzed for each treatment 
condition. 
3.2.4. Experimental parameters 
 Mass spectrometer. A Thermo LTQ Orbitrap XL mass spectrometer (Thermo, 
Waltham, MA) was utilized in positive ionization mode with an ionization voltage of +4.5 
kV applied to the conductive union during analysis. Settings of the mass spectrometer 
used in experiments include 60,000 resolution (m/∆m) at m/z 400, 1 microscan, 100 ms 
maximum injection time, and AGC (automatic gain control) on. The mass range used 
was m/z 100-1500. 
Coupling the integrated cell manipulation platform with the Single-probe mass 
spectrometry technique. To perform experiments on live suspension cells, the ICMP 
was positioned such that the Single-probe’s nano-ESI emitter was centrally positioned 
at the inlet of the extended ion transfer tube. The solvent-providing capillary of the 
Single-probe was programmed to deliver solvent (acetonitrile with 0.1% formic acid 
(FA)) at a flow rate of ~150 nL/min. K562 cells (2 mL) were added to the lid of a 35x12-
mm petri dish (Thermo, Waltham, MA) on top of the ThermoPlate, which was set to 
37C to maintain a living environment of cell. Cells in the petri dish lid were monitored 
using the inverted microscope. Once a cell of interest was determined, the cell-selection 
probe was moved adjacent the cell. A gentle suction was applied to the cell-selection 




selection probe tip was then transferred to the tip of the Single-probe. A digital 
stereomicroscope was used to monitor the approach of the cell-selection probe tip 
towards the Single-probe tip for cell transfer. Once the cell-selection probe and Single-
probe created a junction, the suction from the cell-selection device was released to 
transfer the cell into the solvent (acetonitrile) bridge at the tip of the Single-probe for in 
situ, real-time microscale cell lysis (Figure 3-1). The released cellular contents were 
carried by a continuous flow of the solvent and transported to the nano-ESI emitter for 
ionization and MS analysis.  
    A delay time between releasing the cell from the cell-selection probe and MS 
detection of cellular species was observed. For most experiments, ion signals of cellular 
contents were observed within 3 seconds after releasing the cell into the Single-probe 
tip. Ion signals for analyte from each individual cell usually lasts for around 3 seconds 
under optimized experimental conditions. However, this time length may vary depending 
on the individual cell volume, flow rate, and size of the solvent droplet formed between 
the tips of cell-selection probe and Single-probe. 
3.3 Results 
3.3.1. Optimization of ion transfer tubing length 
Prior to coupling the ICMP with the mass spectrometer, the setup was tested 
using suspended HCT-116 and HeLa cells. The optimized tip size for the cell-selection 
probe was found to be ~50 µm (with the diameter of the orifice ~12 µm) to allow a 
gentle suction from the CellTram Vario without obviously changing the morphology of 




the mass spectrometer, an extended ion transfer tube was used to replace the standard 
one equipped with the mass spectrometer. The length of the ion transfer tube was 
altered to give the best conditions for coupling the system to the mass spectrometer 
without sacrificing ion intensity since the signal from an individual cell can be similar to 
background (~1e4). Using a flow rate of 1 µL/min, the total ion current was compared for 
the different ion transfer tubing lengths (100 and 135 mm) for an internal standard (50-
nM deuterated-Irinotecan (m/z 587.28)) diluted with acetonitrile containing 0.1% formic 
acid. The total ion currents were 6.33e8, and 2.02e8 for the 100-mm, and 135-mm ion 
transfer tubing, respectively. However, signal was unable to be seen when coupling the 
transfer tubing with the Single-probe positioned above the ThermoPlate where the 
sampling solution is located due to the large gap between the emitter and mass 
spectrometer inlet. The gap was unable to be decreased due to the position of the 
instruments being coupled. Therefore, the 135-mm ion transfer tubing was utilized for 
further SCMS experiments. The total ion currents were compared between the 135-mm 
ion transfer tubing and the 20-mm ion transfer tubing utilized in previous Single-probe 
MS experiments. Using 50-nM standards of 15N-gemcitabine (m/z 267.075) and d-OSW-
1 (m/z 895.463) dissolved in acetonitrile, the analyte signal was tested for each 
compound. For the extended ion transfer tubing, the average relative abundance was 
4.65x104  1.56x104 compared to 3.98x105  2.28x105 using the shorter ion transfer 
tube to test 15N-gemcitabine.  However, the higher-mass compound (d-OSW-1), more 
indicative of analyte extracted from cellular content, gave more similar abundances of 
9.28x104  8.51x104 and 7.45x104  4.18x104 for the shorter and longer ion transfer 




µm) was found to be 250 mm with ~135 mm external part exposed to ambient 
conditions. 




Figure 3-2. Graph depicting the temperature dependence on intensities for compounds 
of various masses. Reprinted with permission from Standke et al.90 Copyright 2019 
American Chemical Society. 
 
To minimize the ion loss due to a longer ion transfer tube, experiments were 
performed to evaluate the effect of temperature of the extended ion transfer tubing on 
ion intensities (Figure 3-2). A heating coil with the temperature control unit was 
wrapped around the external part of the ion transfer tube, and the ion intensities of the 
standard calibration solution containing the drug compound was measured under a 
series of temperatures. In general, the ion signal intensities for analytes in higher mass 
ranges increased with increasing temperature and reached a maximum around 225C. 
However, due to the breakdown of gemcitabine and cellular metabolites at elevated 




The ion transfer tube was wrapped with coiled fiberglass insulating tubing 
(MULTICOMP, Newark element14, Chicago, IL) and heated using a POWERSTAT 
Variable Autotransformer (Superior Electric Co, Bristol, CT). Temperature was 
measured using a 6802 II Digital Temperature Thermometer (Signstek, Wilmington, 
DE). Positive ionization mode calibration solution (Caffeine m/z 195, MRFA m/z 524, 
and Ultramark m/z 1322, 1422, and 1522) was supplemented with gemcitabine (m/z 
264.077) and PC 34:1 (m/z 760.588) to give a broad mass range of analyte to monitor. 
A flow rate of 0.5 µL/min was used to continuously deliver solution to the tip for 
ionization using a voltage of 2.5 kV for direct injection.  Signals for analyte under m/z 
500 decreased as the ion transfer tubing was heated and were at or below noise level 







Figure 3-3. Zoomed in spectrum from a single cell showing the representative species 
(m/z 750-850). Structure confirmation of the labeled ions was performed through MS/MS 
analysis (Figure A1). Reprinted with permission from Standke et al.90 Copyright 2019 
American Chemical Society. 
 
 
   K562 cells in both control and drug-treated groups were subjected to the SCMS 
measurement.  Three abundant cellular lipid (phosphatidylcholine (PC)) peaks (PC(34:4), 
PC(36:4), and PC(38:5) at m/z 754.536, 782.567, and 808.583, respectively (Figure 3-
3)) were monitored throughout the experiment to ensure cells were transferred and 
analyzed.112,113,122  These common species have been observed in our previous  studies 





Figure 3-4. Mass spectra obtained from treating individual K562 cells with: (A) 
gemcitabine (1 µM, 1 hr) (B) taxol (1 µM, 1 hr) and (C) OSW-1 (100 nM, 4 hr). Reprinted 
with permission from Standke et al.90 Copyright 2019 American Chemical Society. 
 
 
K562 cells were subjected to treatment with various anticancer drug compounds 
(gemcitabine, Taxol, and OSW-1) to demonstrate the versatility of analyte that could be 
extracted from individual suspended cells. Gemcitabine (1 µM) and Taxol (1 µM) were 
incubated with cells for 1 hr. OSW-1 (100 nM and 1 µM) were incubated with cells for 4 
hours and 2 hours, respectively.  In addition to a large number of cellular metabolites, all 




drug compounds were unable to be detected in the PBS, in which the K562 cells were 
suspended or untreated cells (Figure 3-4), indicating that they were released from cells 
during cell lysis and not from the sampling solution. 
 
Figure 3-5. Zoomed-in mass spectra showing molecular profiles (m/z 800─900) for (A) 
untreated and (B) treated (100 nM Taxol for 24 hours) single K562 cells. Reprinted with 





Figure 3-6. PCA showing the overall difference of metabolic compositions of single K562 
cells in the control and drug treated (100 nM Taxol for 24 h) groups. Reprinted with 
permission from Standke et al.90 Copyright 2019 American Chemical Society. 
 
 
The ICMP coupled to the Single-probe SCMS was also utilized for the analysis of 
global metabolic changes in K562 cells following a 24-hour treatment with Taxol (100 nM). 
The SCMS data were subjected to pretreatment, including background removal, noise 
reduction, peak alignment, and intensity normalization using Geena2 prior to analysis 
using MetaboAnalyst.132,133 Under our experimental conditions, the physiological profiles 
of cells were not significantly changed by drug treatment; however, their molecular 
compositions were drastically changed (Figure 2-4). Principle Component Analysis 
(PCA) was performed to illustrate the differences of molecular profiles of cells between 




data points in the PCA plot reflects the heterogeneity of cells in the same group.134 In 
total, the abundances of 78 metabolites were significantly changed (p<0.05 from t-test) 
upon drug treatment. For further identification of compounds of interest determined from 
SCMS experiments, cell lysates were prepared using drug treated cells (100 nM Taxol 
for 24 hours) and subjected to the complementary MS/MS analysis. Monoglycerides (MG) 
and diglycerides (DG) comprised many of the significantly-changed metabolites. For 
example, upon treatment with Taxol, DG(44:6) is significantly down-regulated, while 
MG(16:0) and MG(18:0) are significantly up-regulated (Figure A2). These results 
illustrate a stark difference between these two groups, including multiple significantly 
up/down- regulated metabolites, which demonstrates the capability of this technology to 
identify global metabolic changes within individual, live suspension cells.  
3.4 Conclusion 
    In summary, the Single-probe SCMS technique has successfully been coupled with an 
integrated cell manipulation platform for the analysis of suspended cells (K562) in 
solution. This integrated system allows us to observe and select individual cells 
suspended in solution. The selected cell is transported to the Single-probe tip, where a 
rapid single cell lysis occurs in an acetonitrile droplet. Released cellular contents are then 
immediately analyzed by a high-resolution mass spectrometer. More than 30 total cells 
were analyzed using this integrated SCMS system, and different cellular metabolites were 
found between treated and control cell groups. Complementary MS analysis of cell lysate 





    This integrated system is suitable for the analysis of cells present in solutions, such as 
bodily fluids, with minimum sample preparation. The complex matrix is largely excluded 
from MS analysis by selecting a cell of interest for analysis with a probe not utilized for 
analysis, so minimal or no solution is extracted. With the ability to analyze small sampling 
volumes, it is feasible that the integrated cell manipulation platform can be used for rapid 
analysis of individual cells derived from patients in situ, which could allow for 
unprecedented personalization of drug administration.  
 
Safety Considerations. Both glass and silica capillaries pose a needle-stick hazard, 
so these items must be handled with caution. Standard safety protocols were enforced 
for the handling of chemicals and culturing and treating of cell lines.  
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Chapter 4 :  Quantification of Drug Molecules in Live Single Cells 
using the Single-probe Mass Spectrometry Technique 
 
4.1. Introduction 
Single cell analysis (SCA) is transforming the biological sciences, making its 
greatest impact in the fields of neuroscience, immunology, and oncology, and it  promises 
to enhance our understanding of individual cells in numerous other contexts.42 Cell-to-cell 
heterogeneity dictates a multitude of functions for homeostasis and development of 
disease states. Since a cell is the basic unit of multicellular organisms, understanding 
functions of organisms in health and disease is aided by understanding cell heterogeneity 
and how it changes during these processes. Compared with the traditional methods that 
are based on the population-averaged studies, SCA can provide a more nuanced analysis 
of the underlying biological mechanics of the system being studied.135 SCA encompasses 
a variety of analytical techniques, including single cell genomics (e.g., DNA and RNA 
sequencing), single cell transcriptomics, single cell fluorescent tagging, Raman 
spectroscopy imaging, and others.6  
Single cell mass spectrometry (SCMS) is a nascent field that has gained great 
interest in  broad areas of research.2,42,106,136,137 Mass spectrometry (MS) is a versatile 
technique to simultaneously analyze a large number of molecules in a short period of 
time. Traditional MS approaches to cell analysis are restricted to a population of cells 
(e.g., cell lysate), where an averaged result is obtained. Recent advancements in high 
mass resolution MS have allowed for the confident identification of a large number of 
molecules,138 and improved sensitivity enables MS to be applied at the single-cell level, 




peptidomics45,139 and proteomics.91 Current SCMS techniques can be broadly 
categorized into two main approaches, non-ambient and ambient techniques, based on 
their sampling and ionization environments. Non-ambient techniques include matrix 
assisted laser desorption/ionization (MALDI) MS100,119,140,141 and time-of-flight secondary 
ion MS (TOF-SIMS),102,103 which are capable of high spatial resolution43 for cellular and 
sub-cellular resolution analysis of the cell organelles.39,101,142 However, non-ambient 
techniques require obligatory sample pretreatment and a vacuum sampling environment, 
which is not suitable for live cell analysis. Ambient SCMS techniques enable the study of 
single cells in their native conditions with little or no sample preparation, allowing live cells 
to be analyzed. Because cells’ metabolites can rapidly change upon the variation of their 
environment, molecular information obtained from live cells has higher fidelity reflecting 
cell status.91 Reported ambient SCMS techniques include laser assisted electrospray 
ionization (LAESI) MS, single cell capillary electrophoresis (CE) ESI MS, probe ESI MS, 
and live single-cell video-MS (live MS).69  
Recently, we have introduced the Single-probe MS technique for in situ MS 
analysis of live eukaryotic cells in real time.46,48,109 The Single-probe is an integrated 
micro-scale sampling and ionization device that can be coupled with a mass spectrometer 
for multiple applications. The Single-probe tip (~6-10 μm) is small enough to be inserted 
into single cells for direct liquid-microextraction of cellular contents followed by immediate 
MS detection. This technique has been used to analyze cellular metabolites of single 
cells, including cancer cells48,80,85,86,90,109 and algae cells.88 In addition, the Single-probe 




imaging of biological samples48,82,83 and analysis of extracellular molecules inside live 
multicellular spheroids.87 
Discoveries in fundamental research as well as industrial and clinical applications 
often require reporting relative or absolute quantities of target molecules. Unfortunately, 
many of the existing spectroscopic143 and MS methods cannot perform quantitative 
analysis on broad ranges of molecules. Over the last decade, researchers have devised 
various MS techniques to quantify analyte from prepared biological samples. Most 
metabolomics studies introduce an internal standard, such as a stable isotope-labeled 
compound, to aid in quantification by plotting relative intensities of the ion pairs to estimate 
the relative amount of target molecules. Although progress has been made in quantifying 
molecules from live single cells, quantitative analysis of species of interest at the single-
cell level is still extremely challenging due to the limited amount of sample present in 
individual cells and a lack of sensitive bioanalytical techniques.  
Semi-quantitative MS analysis has been performed using vacuum-based 
techniques. MALDI was used for one of the earliest reported quantifications of low 
molecular compounds, including the neurotransmitter acetylcholine and peptides from 
biological samples of interest.92 Since then, MALDI-TOF and MALDI-MSI (MS imaging) 
have been explored for semi-quantitative analysis using stable isotope labeling, relative 
ratio comparisons, or mapping cellular images for quantitation at the single-cell level.91  
Ambient MS techniques have also been developed at the individual-cell level. For 
example, the Masujima group reported relative quantification of molecules at the cellular 
level using live single-cell video-mass spectrometry to obtain a ratio of isotopically-labeled 




unlabeled-compound ratios. Recently, label-free quantification of proteins in individual 
frog embryos was performed using ion currents to estimate concentrations using capillary 
electrophoresis micro-electrospray ionization (µ-ESI) for high resolution MS.91 In addition, 
nano-ESI with electroosmotic extraction has been used to quantify the amount of glucose 
in onions,66 and nano-DESI has quantified phosphatidylcholine from human cheek cells.72  
New developments in label-free MS increase the feasibility of the methods for use 
in individualized chemotherapeutic regimens since one of the aims in metabolomics is 
quantitation of metabolites to evaluate changes in response to disease, treatment, and 
environmental and genetic perturbations. Successfully quantifying molecules (e.g. drug 
compounds) in single cells can potentially revolutionize fundamental research and clinical 
tests. In the present study, we employed the Single-probe SCMS technique to directly 
quantify the absolute amount of the drug molecule, irinotecan,74 inside live single cancer 
cells.  
4.2 Methods 
4.2.1. Single-probe fabrication protocol.  
The fabrication protocols of the Single-probe are detailed in our previous 
publications,46,48,82 and only brief procedures are provided here. Single-probe fabrication 
utilizes a laser puller (P-2000 Micropipette Laser Puller, Sutter Instrument Co., Novato, 
CA) to evolve dual-bore quartz tubing (outer diameter (OD) 500 µm; inner diameter (ID) 
127 µm, Friedrich & Dimmock, Inc., Millville, NJ, USA) into a sharp-tipped needle. A 
solvent-providing capillary (OD 105 µm; ID 40 µm, Polymicro Technologies, Phoenix, AZ, 
USA) and a nano-ESI emitter produced from the same fused silica capillary are 




Bonding Adhesive, Prime-Dent, Chicago, Il, USA). To conveniently use the Single-probe 
in the experiment, the device is secured onto a glass slide using regular epoxy glue. The 
glass slide is then held by a flexible clamp holder (MXB-3h, Siskiyou, Grants Pass, OR) 
as shown in Figure 4-1. For SCMS experiments, the Single-probe tip is inserted into a 
cell, and the sampling solvent, which contains the internal standard, is continuously 
delivered into the cell through the solvent-providing capillary. The cellular contents are 
extracted by the sampling solvent and withdrawn by capillary action towards the nano-
ESI emitter, where the extracted molecules and internal standard are immediately ionized 
for MS analysis (Figure 4-1).  
 
 
Figure 4-1. qSCMS experimental setup with individual cells highlighted in the 








4.2.2. Glass chips containing microwells for qSCMS experiments.  
In our qSCMS experiments, it is critical to extract the entire cellular contents and 
delivered solution of the internal standard, which are needed to derive the quantity of 
species of interest inside single cells. Custom glass microchips with microwells (radius: 
55 µm, depth: 25 µm; Blacktrace Inc., MA) were utilized, in which cells were retained in 
microwells through overnight incubation prior to MS measurements (described in the 
following section). Single cells from wells are monitored using a top-view digital 
stereomicroscope (Figure 4-1).  
 
4.2.3. Cell sample preparation.  
The adherent, mammalian cell lines used in these experiments included HeLa 
(cervical cancer) and HCT-116 (colon cancer), which were cultured using DMEM and 
McCoy’s 5A media, respectively. Each media was supplemented with 10% FBS and 1% 
penicillin-streptomycin. Cell lines were passaged around 85% confluency.  
Cell Preparation for qSCMS Experiments. For single-cell experiments, a glass 
microchip containing microwells was placed into each well of a 6-well plate. 400 µL of cell 
suspension (~150,000 cells) solution was added into 3.6 mL of cell culture medium for 
overnight incubation, allowing cells to be attached to the glass microchip.  
For drug treatments, the growth media in the well was first aspirated. Then, an 
appropriate amount of irinotecan solution dissolved in complete media (media that 
contains FBS and penicillin-streptomycin) was added into the well containing the glass 
microchip with cells, adding 4 mL of solution to ensure the chip is fully covered (with final 




(0.5 and 1 h). Cell-containing glass microchips were then rinsed with 5 mL of incomplete 
cell culture media (FBS- and penicillin-streptomycin-free media) to remove residual drug 
molecules on the cell and slide surfaces prior to measurement. Single cells retained in 
individual microwells (i.e., one cell per microwell) were selected for quantitative SCMS 
measurements.  
Cell Lysate Preparation. The results obtained from our SCMS studies were 
compared with those from the traditional cell population analyses: LC/MS analysis of cell 
lysates. In the traditional LC/MS studies, the moles of analyte inside of a single cell were 
estimated by taking the total amount of analyte divided by the total number of cells. For 
cell lysate preparation, cells were cultured in 6-well plates under the same conditions as 
those used in the cell preparation for SCMS experiments as described in the previous 
section. To duplicate the cell growth environment in the SCMS experiments, a glass slide 
was placed at the bottom of each well for cell attachment. Upon finishing drug treatment, 
cells were rinsed using PBS (phosphate buffered saline) and detached from cell culture 
plate using trypsin. Cells were then transferred into 1.5-mL Eppendorf tubes and 
centrifuged to prepare cell pellets. One tube of cells was used to count the cell number. 
The remaining five tubes were used to prepare cell lysate samples through a solvent 
extraction approach, which was conducted by adding ACN(50%) / MeOH(50%) solution 
that contains the internal standard (i.e., deuterated-irinotecan) into each tube. Cell 
extraction was centrifuged, and the supernatant was withdrawn followed by drying. The 
dried samples were dissolved in 200 µL of ACN (12%):H2O (88%), and then analyzed 
using a Waters nanoACQUITY UPLC (C-18 column) coupled to a Thermo LTQ Orbitrap 






Figure 4-2. MS/MS of irinotecan from an individual HCT-116 cell. 
 
 
4.2.4. qSCMS experiments and data processing.  
The qSCMS experiments were carried out using the same experimental setup with 
similar operation procedures as detailed in our previous publications,46,48  and only 
outlined information is provided here. The Single-probe SCMS setup includes a Single-
probe (attached to a glass slide), a digital stereomicroscope, a USB digital 
stereomicroscope, a computer-controlled XYZ-translational stage system, and a Thermo 
LTQ Orbitrap XL mass spectrometer (Figure 4-1).  To conduct a quantitative SCMS 
experiment, the microwell slide containing cells is attached to the motorized XYZ-stage, 
and sample movement is controlled using the LabView software.144 Upon finding a target 




monitored using microscopes. The sampling solution was prepared by adding the 
deuterated-irinotecan into methanol (50%)/water (50%), and it was continuously delivered 
using a syringe pump at a flow rate of ~25 nL/min; the actual flow rate needs to be 
optimized for each Single-probe device. To determine the optimal concentration of 
deuterated-irinotecan used in the experiments, a series of concentrations ranging from 
10 nM to 1 uM were tested. 50 nM was selected as the optimized concentration of 
deuterated irinotecan because it provided ion intensities that were within ~10 times of the 
regular irinotecan, allowing for accurate quantitative MS measurements to be conducted 
within a relative narrow linear dynamic range. To eliminate any potential artifacts related 
to the selections of sampling solvent flow rate and internal standard concentration, we 
have carried out statistical analysis of results obtained under different conditions, and no 
significant difference was observed. MS analyses were performed using the following 
parameters: mass resolution 60,000 (m/Δm), 4.5 kV (positive mode), 1 microscan, 100 
ms max injection time. For more confident identification of species of interest, MS/MS 
analyses were conducted using collision induced dissociation (CID) (Figure 4-2). MS/MS 
was performed to confirm the detection of both irinotecan and deuterated-irinotecan using 
following parameters: isolation width 1.0 m/z (± 0.5 m/z window) and normalized collision 





Figure 4-3. Spectra depicting ion signals (a) before cellular analysis, (b) during analysis, 




To quantify the total amount of irinotecan inside of live single cells, a 
comprehensive MS data analysis was carried out. The insertion of the Single-probe tip 
into an individual cell and extraction of intracellular molecules were confirmed from 
significant changes of mass spectra during the experiment: ion signals changed from the 
solvent background through the culture medium to the cellular metabolites (Figure 4-3). 
Particularly, for the drug treated cells, the ion signal of the regular irinotecan ([C33H38N4O6 
+ H]+) was only observed after the cell was penetrated by the Single-probe, whereas the 
deuterated drug compound ([C33H28D10N4O6 + H]+) was continuously observed through 
the entire data acquisition time. We estimated the moles of irinotecan inside of live single 
cells (x) by taking into account multiple factors, including the integration of the ion 
intensities of the target molecule (∑A) and internal standard (∑B), the concentration of 
the internal standard (c), the flow rate of the sampling solution containing the internal 
standard (v), the MS data acquisition time (t) (Equation 4.1, Figure 4-4).  











Figure 4-4. Extracted ion chromatogram for irinotecan (top) and d-irinotecan (50 nM) 
(bottom) depicting the time for drug signal from individual HCT-116 cells (100 nM, 1 h). 
4.3 Results 
4.3.1. Experimental Setup for Quantitative SCMS Experiments.   
Previous Single-probe MS studies have qualitatively obtained the chemical profiles 
of a wide range of metabolites present in cultured mammalian cells.46,82,83,109 Two major 
modifications were incorporated to the establish quantitative SCMS (qSCMS) capabilities. 
First, methodology for internal standard introduction was established. The unique design 
of the Single-probe allows for versatile compositions of sampling solvent to be used in the 




were utilized in our previous reactive SCMS experiments to detect molecular anions in 
positive ionization mode of the mass spectrometer.109 In the current study, the 
isotopically-labeled drug compound (i.e., internal standard) at predetermined 
concentrations in the sampling solvent allows for the quantification of analytes present in 
the individual cells. The second major new experimental modification to the Single-probe 
SCMS method for quantitation is the use of glass microchips containing microwells for 
cell culture and analysis. Previous SCMS experiments were conducted using non-
differentiated surfaces, such as glass microscope cover slides, to immobilize cells for 
convenient cell sampling. However, partial loss of cellular components through diffusion 
may occur during SCMS measurement. In the qSCMS experiments, only individual cells 
inside hemisphere microwells (radius 55 µm; depth 25 µm, Blacktrace Inc.) were selected 
(Figure 4-1), confining any potential analyte release to the well where the cellular 
compounds can be recaptured for analysis. Microscope-guided visualization of the 
Single-probe sampling individual cells in the microwell is performed until sampling the 





Figure 4-5. Limit of detection for irinotecan using the Single-probe qSCMS method (10 
fM). 
 
4.3.2. Limit of Detection. 
 The limit of detection (LOD) was determined by sampling solutions of irinotecan 
at various concentrations using the qSCMS setup. The LOD was determined to be 10 
fM, while the limit of quantification (LOQ) was measured to be 100 fM (Figure 4-5).  
4.3.3. Influence of Flow Rate and Concentration of Internal Standard.  
Flow rate of the sampling solvent, which contains the internal standard, is an 
experimental parameter that must be optimized for each experiment since it varies with 
tip size, emitter length, and distance between the emitter and the mass spectrometer inlet. 
Therefore, it is important to determine if varying the flowrate affects the amount of drug 




same condition were measured at two different flowrates (25 and 50 nL/min). The 
amounts of drug molecules measured at different flowrates were not significantly different 
(p > 0.05). The concentration of internal standard is also critical for qSCMS experiments, 
and it needs to be carefully selected. Excessively high concentrations of the internal 
standard may suppress the ion signals of analytes; however, inadequate abundance of 
internal standard may not be observed during the experiment. To study the effect of 
internal standard concentration, two different concentrations of deuterated-irinotecan 
were tested (25 nM and 50 nM). Over 45 cells treated using the same condition were 
measured using each concentration of internal standard, and the obtained amounts of 
drug molecule were not significantly different (p > 0.05). 
4.3.4. Method Validation.   
Validation experiments were carried out to verify the Single-probe qSCMS 
technique is capable of highly efficiently sampling and detecting target analytes from 
single cells retained in microwells on the glass chip. To split the flow of irinotecan solution, 
three fused silica capillaries were connected to a µT-connector. For precise delivery of 
irinotecan solution into target microwells, the first fused silica capillary (ID: 25 µm, OD: 
360 µm) was chemically etched (using HF) into a sharp needle, which was placed into a 
microwell on the glass chip with the flat end connected to one channel of a T-junction. A 
second capillary with the same length but a larger ID (ID: 50 µm, OD: 360 µm) was 
connected to another channel of the T-connector. The third capillary was connected the 
other channel of the T-connector to deliver the irinotecan solution from the syringe. A 
series of volumes (2-9 nL) of irinotecan solution (10 nM) were delivered into individual 




in those microwells. Similar to the Single-probe qSCMS measurements, this experimental 
setup was utilized with a continuous flow of internal standard (deuterated-irinotecan with 
the same concentration 10 nM) to extract irinotecan in microwells for MS analysis.  
    
Q =  
ΔPπr4
8ηl
     (Equation 4.2) 
where Q is the volume flux, P is the change in pressure, r is the capillary radius,  is the 
viscosity, and l is the capillary length.     
 
Poiseuille’s Law (Equation 4.2) was used to calculate the flow rate from the 
chemically-etched probe, which was used to deliver the irinotecan solution into each 
microwell. We then used the Single-probe qSCMS technique to measure the amounts of 
irinotecan in each well by placing the Single-probe tip into individual microwells containing 
irinotecan. Similar to the measurement operation and data analysis of qSCMS of cells, 
the deuterated-irinotecan internal standard was also used (flow rate was 150 nL/min), 
and the amounts of irinotecan deposited in microwells were calculated. Using Excel, we 
plotted the correlations between the ratio of the areas of irinotecan to deuterated-






Figure 4-6. Graph of the ratio of the areas of irinotecan to deuterated-irinotecan versus 
the ratio of the volumes of irinotecan to deuterated-irinotecan for method validation. 
 
 
A y-intercept of 0 would indicate all the irinotecan loaded into each microwell was 
captured. Our y-intercept of 0.05 suggests most of the irinotecan was captured (Figure 
4-6). Error could come from the small volume available for each microwell, making it 
difficult to inject volumes smaller than individual microwells as well as from capillary 
action, which could draw some irinotecan solution back inside the capillary. A slope of 1 
and a high R2 value would indicate the ratio of volumes and areas of drug compound to 
internal standard are equal, which is a major factor for qSCMS calculations since we are 
using the total intensities as areas under the curve. A slope of 1.01 with an R2 value of 
0.98 suggests the ratios are similar and can be used for calculations (Figure 4-6). These 






Figure 4-7. Box plot depicting the amount of irinotecan (amol) inside individual HeLa 
and HCT-116 cells at varying treatment concentrations and times. 
 
4.3.2. qSCMS of the Anti-Cancer Drug Irinotecan in Human Cancer Cell Lines.  
Single-probe qSCMS analysis of the standard-of-care anti-cancer drug irinotecan 
in individual HCT-116 and HeLa human cancer cells is reported (Figure 4-7 and Table 
4-1). The adherent HCT-116 colon adenocarcinoma and HeLa cervical cancer cell lines 












































































































4-7 and Table4- 1). Single cells inside microwells (i.e., one cell/microwell) were used in 
the quantitative SCMS measurements. Internal standard (d-irinotecan) concentrations of 
25 and 50 nM were used. We collected eight sets of data from both cell lines treated 
under different conditions, and more than 30 cells were measured for each set of SCMS 
experiments. Rank sum tests (Mann-Whitney) 
 were conducted to determine whether there is a statistically significant difference 
of drug quantity between each pair of datasets. In general, the drug uptake amounts from 
individual cells exhibit a broad range of values, which are likely attributed to the 
heterogeneity of individual cells. 
The Single-probe qSCMS measurements show several clear trends connecting 
cellular treatment with intracellular drug levels. Increasing irinotecan treatment 
concentrations in the HCT-116 cellular media from 0.1 to 1.0 µM increased the average 
intracellular irinotecan levels in individual cells. Using the lower drug concentration (0.1 
µM Irinotecan), the drug update amounts were measured as 5.3 ± 5.1 x 10-18 and 8.5 ± 
8.4 x 10-18 mole (attomole or amole) for cells treated for 0.5 and 1.0 hour, respectively. 
Larger amounts of intracellular drug molecules were obtained from cells treated with a 
higher concentration (1.0 µM): 15.2 ± 14.1 and 23.1 ± 16.7 amol for the treatment time of 
0.5 and 1 hour, respectively. The increased drug uptake amounts from individual cells in 
different groups are statistically significant (p < 0.01) (Figure 4-7). In contrast, increasing 
the treatment time from 0.5 to 1.0 hour, while keeping the same drug concentration, has 
no significant effect (p > 0.05) on drug uptake.  
For HeLa cells, a similar trend was found: increasing the drug concentration from 




Cells treated with 0.1 µM irinotecan reported intracellular drug amounts of 1.9 ± 1.8 and 
3.2 ± 3.0 amol for 0.5- and 1.0-hour treatment times, respectively. Increasing the drug 
treatment concentration to 1.0 µM increases the drug uptake amount to 9.8 ± 7.1 and 
14.7 ± 10.4 amol for 0.5- and 1.0-hour treatment times, respectively. Additionally, keeping 
the same drug treatment concentrations (0.1 or 1.0 µM) while increasing the treatment 
time from 0.5 to 1.0 hours has no significant influence (p > 0.05) on intracellular drug 
levels. The qSCMS studies suggest that both HCT-116 and HeLa cells rapidly absorb 
drug compound from media. 
Our experiments clearly show that cellular drug uptake amounts vary between 
HCT-116 and HeLa cell lines (Figure 4-7). Although both cell lines exhibit very similar 
trends of drug uptake amount, the intracellular drug amounts in single HCT-116 cells are 
significantly higher (p < 0.001) than those in single HeLa cells treated under the same 
conditions in all cases. These differences are likely attributed to multiple reasons. First, 
the cell sizes of these two cell lines are different. The average volume of an HCT cell  
(3.26 ± 0.11 picoliters) is about 1.3 times as the volume of a single HeLa cell (2.6  0.4 
picoliters),127,145 so larger cells may have higher drug uptake amount. Second, it is 
possible that HCT-116 cells have a higher efficiency of irinotecan uptake since irinotecan 
has shown to have a greater aptitude towards the treatment of colon cancer than cervical 
cancer.146 
4.3.3. Comparison of SCMS and LC/MS Results.  
For comparison studies, we prepared cell lysate samples (see “Cell Sample 
Preparation”) and conducted traditional LC/MS experiments to measure the average 




concentrations was added during the preparation of cell lysate. Using nano-UPLC/MS, 
ion signals of both regular and deuterated-irinotecan were measured. The average drug 
amount in a single cell was estimated by considering multiple factors, including the peak 
areas of both regular and deuterated-irinotecan, the concentration of deuterated-
irinotecan in cell lysate samples, and the total number of cells in each sample.  
In general, a similar trend for both SCMS and LC/MS has been observed: a higher 
drug treatment concentration and/or longer treatment time results in higher drug uptake 
for both cell lines. However, the amounts of irinotecan measured from quantitative SCMS 
experiments are significantly higher than those from LC/MS experiments for both cell lines 
treated under all conditions (Table 4-1). For example, HCT-116 cells that underwent 0.1 
µM treatment for 1 hour gave values of 8.5 ± 8.4 amol and 2.5 ± 0.8 amol for SCMS and 
LC/MS experiments, respectively. The t-test results indicate that these results are 
significantly different (p < 0.001). Similarly, treating cells with 1 µM irinotecan for 1 hour 
gave averaged values of 23.1 ± 16.7 amol and 11.6 ± 3.4 amol for SCMS and LC/MS 
measurements (p < 0.001), respectively. A similar trend was found for 0.5-hour drug-
treated groups under different drug treatment concentrations (0.1 µM and 1 µM) in HeLa 
cell line experiments.  
The difference between these two methods is likely due to two major reasons. Cell 
heterogeneity in SCMS experiments can attribute to the large standard deviation, and the 
possible drug loss during the lengthy LC/MS sample preparation process could contribute 
to SCMS having larger values. First, cellular heterogeneity is likely to influence cellular 
phenotypes since every cell is unique and is the product of its own particular genome, 




Table 4-1. Amount of irinotecan (amol) found inside single cells for varying treatment 
times and concentrations using both qSCMS and LCMS analysis. (a) Results from HeLa 









100 nM, 0.5 h 1.9 ± 1.8 1.3 ± 0.5 
100 nM, 1 h 3.2 ± 3.0 1.9 ± 1.1 
1 µM, 0.5 h 9.8 ± 7.1 3.9 ± 3.0 









100 nM, 0.5 h 5.3 ± 5.1 2.5 ± 0.2 
100 nM, 1 h 8.5 ± 8.4 2.5 ± 0.8 
1 µM, 0.5 h 15.2 ± 14.1 10.5 ± 1.7 





It is becoming clear that the differences among individual cells, even within a 
supposedly homogeneous cell-type, can influence the behavior of a biological system.72 
All of these differences among individual cells are critical for the cell functions, which may 
alter the capability of drug uptake. Second, the difference of cell sample preparation is 
likely to induce variance between the different measurements. SCMS involves minimal 
sample preparation, so there is less of a chance of drug compound loss between sample 
preparation and measurement. In contrast, cell lysate samples used for traditional LC/MS 
experiments involve multiple-step preparation. After anti-cancer drug treatment, cells 




detachment, multiple rounds of rinsing cells and centrifugation, and organic solvent 
extraction. Unfortunately, the internal standard cannot be added into cell samples during 
these steps to compensate for drug compound loss during these steps, and it is 
impractical to measure the portion of drug compound lost during these steps. In contrast, 
drug treated cells are rinsed with either untreated (FBS-free) culture media or PBS and 
followed by immediate analysis for qSCMS experiments, minimizing drug compound loss 
from target single cells. 
Since cells were measured in a near-native environment in SCMS experiments, 
the results are likely more representative of cellular status than LC/MS experiments. 
However, our quantitative SCMS approach has its own limitations. First, solvent 
extraction is performed at the single-cell level to extract drug compounds for MS analysis, 
which makes this method suitable to detect and quantify free and loosely-bonded drugs 
inside single cells. However, if drug compounds form covalent bonds with DNA or 
proteins,91,147 they are not likely to be extracted by solvent during the SCMS 
measurement. Second, we measured approximately 30 cells for each treatment condition 
due to the limited SCMS experimental throughput. An increased throughput of the 
quantitative SCMS technique will significantly enhance experimental efficiency. Third, our 
current studies provide the absolute amount of drug compound inside single cells. 
However, we were unable to measure the volume of cells using the current experimental 
setup to provide intracellular drug concentration, which is likely to be of great interest for 
fundamental research and the pharmaceutical industry. Therefore, future technology 
development and more detailed studies are needed to enable deeper understanding of 





In the present study, we utilized the Single-probe qSCMS technique to measure 
the absolute amount of the anti-cancer drug compound irinotecan from live single cells in 
real time. Two cell lines, HCT-116 and HeLa, were used as the model systems and 
subjected to drug treatment using a series of concentrations and times. The sampling 
solvent containing deuterated-irinotecan, the internal standard, was delivered to the 
Single-probe device to perform microscale extraction of cellular contents. Both irinotecan 
and its internal standard were simultaneously detected in real-time MS analysis, and the 
absolute drug uptake amounts from individual cells were estimated. Our results indicate 
that for single cells treated using the same conditions, drug uptake amounts were broadly 
distributed. For cells treated under different concentrations and times, drug concentration 
is likely to have a more significant influence on the drug uptake amount than treatment 
time. Comparison between the two cell lines indicate that HCT-116 cells contain 
significantly more irinotecan than HeLa cells. Drug uptake amounts obtained from single 
cells were also compared with the results measured from cell lysates using LC/MS. The 
results obtained at the single-cell level were significantly higher than those from 
population cell measurements, which can be attributed to cell heterogeneity and potential 
drug compound loss during cell lysate preparation. This qSCMS technology is applicable 
of the analysis of many other types of drug compounds, drug metabolites, and cellular 
metabolites of interest and can lead to better understanding of pharmacokinetics and 
potential applications of compounds in precision medicine, including patient samples, to 
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Chapter 5 :  Single Cell Mass Spectrometry Quantification of 
OSW-1 Kinetics 
 
5.1 Introduction  
Intracellular drug incorporation provides information that is essential for the 
advancement of personalized cancer therapeutics. The time for incorporation of anti-
cancer compounds in cancer cells can provide insight towards the toxicity and metabolism 
of the drug, which can determine drug candidacy for a patient.148 In drug development, 
quantitative measurement of drug uptake rate is essential to evaluate the efficacy of the 
drug towards a specific type of cancer. OSW-1 (3beta,16beta,17alpha-trihydroxycholest-
5-en-22-one 16-O-(2-O-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1-->3)-(2-O-acetyl-
alpha-L-arabinopyranoside)) is a naturally-occurring compound isolated from the 
chincherinchee bulbs (Ornithogalum saundersiae) exhibiting antiproliferative properties 
of cultured human cell lines with half-maximal inhibitory concentrations (IC50) in the sub-
nanomolar range.149,150 OSW-1 belongs to the ORPphil-in family of natural products due 
to its targeting of oxystersterol binding protein (OSBP) and OSBP-related protein 4L 
(ORP4L).151 Although it is suggested that OSBP and ORP4 are the efficacy targets of 
OSW-1, its cytotoxic mechanism of action is highly enigmatic.150,152 Understanding the 
pharmacokinetic and pharmacodynamic properties of OSW-1 and other potential 
chemotherapeutic agents could lead to important discoveries regarding the effectiveness 
of their dosages. The average amount of drug compounds in individual cells is traditionally 
measured using bulk analysis methods, such as liquid chromatography mass 
spectrometry (LCMS), of samples prepared from populations of cells (i.e. cell lysate 




mass spectrometry (LCMS) include a lengthy sample preparation process, requirement 
of a large number of cells, and inability to describe cellular heterogeneity. Particularly, the 
lengthy sample preparation process is needed for these traditional experiments, resulting 
in inaccurately studying of pharmacokinetic or pharmacodynamic properties of anti-
cancer compounds. To thoroughly understand the efficacy of these compounds on 
various cell types (i.e. cancerous or non-cancerous), it is important to investigate drug 
interactions on the single-cell level.  
 Single cells analysis (SCA) techniques for eukaryotic cells currently include 
microfluidics, DNA and RNA sequencing,117,118,153 mass spectrometry (MS),2,4,42,108,119,137 
cytometry,4,6,16,17 and Raman spectroscopy imaging,154 amongst others. However, the 
need for sample preparation for many of these methods could change the morphology of 
cells and deter their ability to retain cellular characteristics. Thus, it is critical to develop 
bioanalytical techniques capable of analyzing cells in real time in a near-native 
environment. Single cell mass spectrometry (SCMS) is becoming more widely used, 
especially the subcategory of SCMS involving ambient ionization, for the ability to give an 
abundance of information utilizing a label-free process with minimal sample preparation. 
Recently, our lab has used the Single-probe MS technique to analyze various cellular 
metabolites and drug molecules real time, both qualitatively46,48,83,87,109 and quantitatively 
(Chapter 4), inside individual mammalian cell lines for SCA or tumor imaging. In this work, 
we expand the versatility of quantitative single cell mass spectrometry (qSCMS) to include 
the analysis of pharmacokinetic and pharmacodynamic data for OSW-1 in both HCT-116 




5.2 Experimental Section 
5.2.1. Materials and Reagents.  
LCMS grade acetonitrile and methanol were purchased from Sigma Aldrich (Saint 
Louis, MO) and used as solvents for both SCMS and LCMS experiments. A P-2000 
Micropipette Laser Puller from Sutter Instrument Company (Novato, CA) was used to pull 
Friedrich & Dimmock, Inc. (Millville, NJ) dual bore quartz tubing for both sets of 
experiments. Fused silica capillaries were purchased from Polymicro Technologies 
(Phoenix, AZ). Glass microchips were purchased from Blacktrace (Norwell, MA), a sister 
company of Dolomite Centre (Royston, Herts, UK). Before use, each microchip was 
coated with poly-D-lysine (MW 70,000 – 150,000) to improve cell attachment. 
5.2.2. Glass Microchip Maintenance. 
Prior to use, glass microchips were coated with poly-D-lysine. Poly-D-lysine (5 
mL) was placed into 3 wells of a 6-well plate, and PBS was placed in the other 3 wells. 
Using forceps, a microchip was inserted into a poly-D-lysine-containing well for 5 
minutes. After 5 minutes, the chip was transferred to a well containing PBS. After 
washing, the glass microchips were exposed to UV light for 2 hours prior to being used 
for plating.  
Before use, glass microchips were rinsed with complete McCoy’s media (5 mL, 3 
times). After use, the chips were exposed to UV for at least 2 hours prior to reuse. 






5.2.3. Sample Preparation.  
Both HCT-116 and T24 cell lines were grown in McCoy’s medium supplemented 
with 10% synthetic fetal bovine serum and 1% penicillin-streptomycin. All cells were 
maintained in an incubator at 37C under 5% CO2, and they were passaged around 75% 
confluency. T24 and HCT-116 cells were grown up for 2 days prior to treatment. To avoid 
mutations, only cells under passage number 25 that were in culture less than 2 months 
were utilized in the experiments. 
 Cells were plated in 6-well plates on glass microchips (28 mm) containing 
chemically-etched microwells (width: 55 µm; depth: 25 µm) to prevent sample loss that 
could occur as the Single-probe penetrates each cell. For each treatment, culture medium 
for the desired well was aspirated and replaced with fresh medium containing 100-nM 
OSW-1 (4 mL) and allowed to incubate at 37C for the duration of the treatment time. 
Prior to analysis, each microchip was washed with FBS-free media (5 mL) to avoid 
detection of the drug from extracellular content. 
5.2.4. Single Cell Mass Spectrometry Protocol.  
 Single-probe Fabrication. Single-probes were fabricated utilizing a previously 
published protocol;155 therefore, only a brief summary is given here. Dual-bore quartz 
tubing (OD: 500 µm, ID: 127 µm) was pulled into a sharp needle using a laser puller to 
give a final tip diameter of ~5 µm. A silica capillary (OD: 105 µm, ID: 40 µm) was placed 
into one bore to act as the solvent-providing capillary, and a nano-ESI emitter pulled from 




UV curing resin, and the finished probe was secured to a glass slide using Epoxy glue for 
easy coupling to the mass spectrometer with a flexible clamp holder.  
 Single-probe Mass Spectrometry Setup. The nano-ESI emitter was aligned with 
an extended ion transfer tube for coupling with the Thermo LTQ Orbitrap XL mass 
spectrometer (60,000 m/∆m, 1 microscan, 1 ms maximum injection time). The cell-
containing glass microchip was then placed on an X, Y, Z-translational stage controlled 
by the LabView software package that allows the stage to be moved precisely in 0.1-µm 
increments. High voltage (~4 kV) was applied to a conductive union that connected the 
probe to a syringe containing the internal standard (50 nM d-OSW-1) dissolved in 
acetonitrile with 0.1% formic acid. Once a single cell was selected using a top-view 
stereomicroscope, penetration was achieved by raising the stage in the Z-direction.  
 Data Analysis. Data analysis was attained by exporting the scans from the Xcaliber 
software package into Excel. Then, the analyte signal time and total intensities (integral) 
for both OSW-1 and d-OSW-1 were calculated. By factoring in the flow rate and 
concentration of the internal standard (d-OSW-1), the absolute number of moles of OSW-
1 could be calculated for each cell using a ratio of analyte to internal standard. The relative 
concentration of drug in each cell was estimated using the average cell volume of each 
cell line.   
5.3 Results 
The absolute number of moles of OSW-1 in each individual cell was calculated at 
various time points to determine the pharmacokinetic and pharmacodynamic data, and 
the relative concentration can be estimated using an average cell volume of 3.26 pL and 




compound is present within 15 minutes after OSW-1 treatment (100 nM), and its 
abundance is significantly increased (p < 0.01) until 1 hour for cells treated with 100 nM 
OSW-1 (Table 5-1, Figure 5.1). However, it is likely that OSW-1 establishes intracellular 
concentration equilibrium in HCT-116 cells around 1 hour because the drug amount is not 
significantly changed after that time (p < 0.01).  
 
Figure 5-1. Box plots showing the amount of OSW-1 accumulated in each cell line.  
(a) HCT-116 cells, and (b) T24 cells. (n>20 for each treatment) 
 
 In comparison, T24 cells appear to establish concentration equilibrium at a slower 
rate than HCT-116 cells upon treatment using the same drug concentration. Longer 
treatments (>2 h) lead to drug accumulation, and the greatest values are reached after 4 
hour-treatments (Table 5-1). Our experimental results suggest that the drug uptake rate 
is time-dependent, and it may vary for different cell lines. 
Washout experiments were performed in HCT-116 cells to determine how long the 
drug is retained inside each cell. HCT-116 cells were treated with OSW-1 (100 nM) for 1 
h, which correlates to the treatment time with the maximum amount of drug accumulated. 




HCT-116 cells for up to 24 hours (limit of detection is 10 nM).89 The amount of OSW-1 is 
significantly decreasing from 6 hours to 12 hours, suggesting the drug is metabolizing. 
However, the metabolites of OSW-1 are currently unknown, so they were not able to be 
monitored during this timeframe. 
 




Moles Calculated (& 
Estimated Concentrations) 
HCT-116 
Moles Calculated (& 
Estimated Concentrations) 
 T24 
0.25 4.79 ± 2.47x10-17 1.30- ± 0.892x10-16 
0.5 7.85 ± 4.93x10-17 1.31- ± 0.939x10-16 
1 1.72 ± 1.33x10-16 9.82- ± 5.95x10-17 
2 1.27 ± 0.982x10-16 8.45- ± 8.02x10-17 
4 9.80- ± 9.80x10-17 1.33- ± 1.10x10-16 
6 8.52- ± 6.30x10-17 9.82- ± 6.54x10-17 
12 9.64 ± 6.30x10-17 6.42 ± 5.04x10-17 
  
5.4 Conclusions 
The Single-probe qSCMS was used to quantitatively measure the dynamics of 
drug uptake, particularly at time points that are too short (e.g., within 15 min) to measured 
using traditional analytical methods, such as LCMS, in which lengthy steps of sample 
preparation are obligatory. In addition, our technique is capable of quantifying the 
absolute drug amount inside individual cells, whereas traditional methods, which are 
based on bulk sample measurements, can only provide averaged results with an 




Due to the complexity of cell heterogeneity, even for the cultured cell lines, it is 
challenging to depict the quantitative SCMS results, as the amount of drug measured in 
individual cells, regardless of cell lines or treatment conditions, exhibit a wide distribution. 
Therefore, it is expected to obtain relatively large standard deviations of experimental 
results, especially compared to the small standard deviations of traditionally-established 
methods. It is worth noting that the measurement of each cell cannot be repeated because 
each cell contains a limited volume that is enough for only one measurement. Although 
obtaining the absolute drug concentration in individual cells will tremendously affect 
fundamental studies and clinical applications, our technique cannot provide such 
information at the current state. With microscope-guided experiments, a general cell size 
can be seen before analysis, but wells are chosen without bias: only wells with one cell 
are targeted for analysis, regardless of the size of cell within the well. Without accounting 
for the actual cell volume of each individual cell, it is difficult to give a more accurate 
information of drug concentration. Future work will include establishing a protocol to 
determine both the cell volume and absolute amount of drug during the SCMS 
experiments and provide concentrations of drug compounds in individual cells (Chapter 
6).  
 The amount of OSW-1 measured at various time points within each cell line 
demonstrate the minimum exposure time required for the drug to be absorbed within each 
cell, the length of time to establish chemical equilibrium, and how long the drug is retained 
within each cell. This technology can be applied to other drugs to determine 
pharmacokinetic or pharmacodynamic data towards the metabolism of drugs in various 




aptitude of the drug compound towards killing cancer cells can be determined. Our 
technique can be potentially applied to cells from patients to revolutionize personalized 
cancer regimens in the future (Chapter 6). 
5.5. Acknowledgements 
 The author would like to thank Dr. Anh T. Le for synthesizing the internal 
standard used in these experiments. Also, the author would like to thank Mr. Ryan C. 
Bensen for his help in sample preparation and writing of this manuscript (to be 














Chapter 6 : Single Cell Mass Spectrometry Quantification of the 
Anti-Cancer Compound Gemcitabine: From Cell Lines to 
Patients 
6.1 Introduction 
    Personalized medicine maximizes the efficacy of one’s treatment by accounting for  the 
biological makeup of the individual.156 This practice is currently best characterized in 
oncology, primarily through genotypical identification of key cancer-related genes for 
proper identification and characterization of the tumor.157 However, current drug-dosage 
determination is typically chosen in correlation to the patient’s physical characteristics, 
such as body surface area, and is administered in a scheduled manner.158,159 The efficacy 
of this treatment course is generally conducted through an endpoint analysis, typically 
weeks or months following initial treatment administration. This translates into extended 
periods of time in which patients are required to endure chemotherapy medication with 
its potential associated adverse side effects to determine if the initial treatment was 
effective in overall cancer regression.  
     Therapeutic Drug Monitoring (TDM) is currently used for the determination of drug 
efficacy through quantification of the chemotherapeutic agent in serum at designated time 
points throughout a drug administration regimen.160 The following dosage is administered 
considering the previously- calculated serum concentrations, resulting in a constant 
serum concentration of the chemotherapeutic agent. A major drawback associated with 
TDM arises from the pharmacokinetic/ pharmacodynamic diversity of each individual, 
which skews drug quantification at the primary tumor site.160,161 Alternatively, the drug 




sampling and lacks the validation of therapeutically-relevant drug concentrations within 
cancer-specific cells. 
     The heterogenetic disease state of cancer is becoming increasingly characterized as 
an abnormal cellular process originating at the single-cell level, contributing to the 
development of the cancer stem cell theory and clinical relevance of circulating tumor 
cells.162–165 Therefore, the development of bioanalytical methods for the detection and 
quantification of disease-relevant compounds on the single-cell level would be a powerful 
tool by providing real-time feedback of therapeutically-relevant treatment efficacy.46 
Single cell analyses have been developing over the past decade, including DNA and RNA 
sequencing, microfluidics, imaging, cytometry, and mass spectrometry (MS).2,117–119,166–
170 New and innovative mass spectrometry methodologies utilizing unique apparatuses, 
ionization technologies, and microscopy could also be applied to single cell mass 
spectrometry (SCMS) technology, progressing the applicability and accessibility of 
SCMS.101,106,171–178 
The prodrug gemcitabine (2′,2′-difluoro-2′-deoxycytidine; dFdC) is a commonly-
used drug known for its synergy with the anti-cancer compound cisplatin and, together, 
form a regimen for the treatment of many cancers, including bladder cancer.179 After 
intracellular uptake, the prodrug is phosphorylated into its active form (2′,2′-difluoro-2′-
deoxycytidine triphosphate; dFdCTP) or is deaminated into its inactive form (2′,2′-difluoro-
2′-deoxyuridine; dFdU).180,181 Gemcitabine has been previously quantified in extracted 
tumor tissue, peripheral blood mononuclear cells (PBMCs), and in plasma.182–185 
However, these methods lack the ability to analyze drug pharmacology in a non-invasive 





Figure 6-1. Schematic of the setup for non-adherent cells, including cells derived from 
the urine of bladder cancer patients. 
 
 
Here, gemcitabine is quantified from individual cells of an adherent bladder cancer 
cell line (T24), non-adherent chronic myeloid leukemia, (K562), and  cells isolated from 
the urine of gemcitabine-treated bladder cancer patients using the Single-probe MS 
technique previously used for the real-time analysis and quantification of individual 
adherent cancer cell lines, algal cells, and spheroids utilizing an integrated cell 






6.2.1. Sample Preparation.  
Adherent Cell Lines. For the adherent bladder cancer cell line model, T24, cells 
were plated according to a previously published protocol. Cite IR. Briefly, T24 cells (1x105) 
are plated into each well of a 6-well plate containing a poly-D-lysine-coated glass 
microchip with chemically-etched microwells (25 µm x 55 µm) and McCoy’s Media 5a 
supplemented with 10% synthetic fetal bovine serum (FBS) and 1% penicillin-
streptomycin (4 mL). Approximately 36 hours after initial seeding, the media in each well 
is replaced with Gemcitabine-containing media at the indicated concentrations and 
incubated at 37C and 5% CO2 for the duration of the treatment time (1 hour). Prior to 
analysis, each glass microchip is rinsed with FBS-free media (5 mL) to avoid the detection 
of Gemcitabine from extracellular species. Cells were tested using the traditional Single-
probe setup, modified for quantification (Figure 6-1).  
 Non-Adherent Cell Lines. The human chronic myeloid leukemia cell line, K562, 
was used as a cell line model for the proposed suspended cell manipulation system. Cells 
were grown in T25 flasks at 37C and 5% CO2 in RPMI media supplemented with 10% 
FBS and 1% penicillin-streptomycin. Prior to treatment (~24 hours), K562 cells (~1x105) 
were seeded out in a T25 flask. The cells were spun at 1500 RPM for 5 min and treated 
with Gemcitabine at the indicated concentrations at a 4-mL volume in a 15-mL Falcon 
tube. After treatment, cells were pelleted at 1500 RPM for 5 minutes at 37C and washed 
3 times with PBS (10 mL). All tubes were resuspended in PBS (3 mL/tube) and were used 




manipulation platform (ICMP) in conjunction with quantitative single cell mass 
spectrometry using the Single-probe mass spectrometry technique. Cite Tech. 
 Bladder Cancer Patient Samples. Two separate groups of bladder cancer patients’ 
urinary cells were analyzed in this study. One group (n=2) was not subjected to 
gemcitabine (untreated), while the other (n=2) received 1000 mg/m2 infusion of 
gemcitabine. The urine was collected in a specimen jar for the analysis of the non-treated 
patients and collected an hour after infusion for the treated patients. The urinary sample 
was processed and analyzed within 3 hours after collecting. Each sample was processed 
as followed:  sample was spun at 1500 RPM for 5 minutes at 37C, followed by washing 
with pre-warmed PBS (20 mL) 3 times. The cells were resuspended in PBS (2 mL), and 
the cell solution was placed into a 3-mL petri dish for analysis using the ICMP. 
6.2.2. Integrated Cell Manipulation Platform.  
The Single-probe setup has been modified to accommodate an Eppendorf cell 
manipulation system, which utilizes both a Single-probe and a cell-selection device that 
allows the analysis of samples from a complex matrix with minimal sample preparation 
(Figure 6-1). The system is composed of an Eppendorf TransferMan cell manipulation 
system, Nikon inverted microscope, a Tokai Hit ThermoPlate, and a glass cell-selection 
device. The cell-selection device was held in place and controlled through an Eppendorf 
TransferMan cell manipulation system. The Single-Probe was controlled through a 
second TransferMan system and stabilized with a flexible arm clamp. This system was 
constructed on a motorized table for convenient coupling to the Thermo LTQ Orbitrap XL 




6.2.3. Glass Cell-Selection Probe Fabrication.  
Single-bore glass tubing (ID: 0.3 mm, OD: 1.1 mm) was transformed into a glass 
cell-selection device using a vertical pipette puller. Briefly, the glass was heated to create 
a tapered tip (~15 µm in diameter) to encompass an individual cell. Once the probe was 
pulled apart, it was placed in a Microforge MF-9 and bent ~45 from its original position.  
6.2.4. Single-probe Fabrication.  
Single-probes were fabricated using a previously published protocol.186 Briefly, 
dual-bore quartz tubing (OD: 500 µm; ID: 127 µm) was pulled into a sharp needle (OD: 
~5 µm) using a micropipette laser puller. Fused silica capillary (OD: 110 µm, ID: 40 µm) 
was placed into one bore as a solvent-providing capillary. The same diameter capillary 
was flame-pulled and placed into the other channel of the dual-bore quartz needle as a 
nano-ESI emitter. The probe was sealed using UV resin and secured on a glass slide with 
Epoxy glue for easy coupling to the flexible arm clamp of either the X, Y, Z-translational 
stage (adherent cells) or TransferMan manipulation system (non-adherent cells). 
6.2.5. Mass Spectrometry Analysis of Individual Cancer Cells.  
The Single-probe’s nano-ESI emitter was aligned with the extended ion transfer 
tube’s inlet. The solvent-providing capillary of the Single-probe was programmed to 
deliver solvent (internal standard dissolved in acetonitrile with 0.1% formic acid) at a flow 
rate of ~100 nL/min. Information regarding the synthesis of 15N-gemcitabine can be found 
in Appendix B. Analysis was performed using a Thermo LTQ Orbitrap XL mass 
spectrometer. Positive ionization mode was used with a voltage of ~4.5 kV applied to the 




for each experiment due to varying tip size, emitter length, and emitter distance from the 
mass spectrometer’s inlet). A resolution of 60,000 and 1 scan/100 ms maximum injection 
time were used. 
 Adherent Cell Line Analysis. The glass microchip was placed on an X, Y, Z-
translational stage controlled through the LabView software package, which allows 
controlled movements in 0.1 µm increments. Cells are monitored using a top-view digital 
stereomicroscope. Once an individual cell is selected, the stage is lifted in the z-direction 
for insertion. Microscale extraction of cellular content occurs and is introduced to the mass 
spectrometer after ionization using the nano-ESI emitter. 
 Non-Adherent Cell Line Analysis. Cells are placed in the lid of an 18-mm petri dish 
placed on a ThermoPlate at 37C to mimic the cellular environment. During analysis, cells 
are monitored using an inverted microscope. Once a cell is chosen, suction is gently 
applied to the glass cell-selection device by changing the mineral oil in the CellTram Vario 
microinjector to secure a cell, and the cell-selection device is lifted in the Z-direction until 
aligned with the Single-probe tip. Once a liquid junction is formed between the two probes, 
suction from the cell-selection device is released for cell transfer. The cell undergoes 
microscale lysis and extraction and is taken up through drag force and capillary action 
before being sprayed into the mass spectrometer for analysis. 
6.2.6. Gemcitabine Quantification.  
For data analysis, files were exported from XCaliber to Excel, and the ratio of the 
intensities between gemcitabine and 15N-labeled gemcitabine was calculated. Taking into 




gemcitabine, the absolute amount of compound (mol) was calculated for each individual 
cell. The relative cellular concentrations were estimated using the average cell volumes 
for each cell line (T24: 7.2 pL, K562: 2.8 pL).131,187 
6.3 Experimental Section 
     Gemcitabine (m/z 264.0781) quantification was performed with the addition of an 
internal standard of isotopically-labeled (15N-labeled) gemcitabine (m/z 267.0703) 
(Scheme B1, Figures B1, B2) into the sampling solvent (acetonitrile with 0.1% formic 
acid). Gemcitabine was first quantified in individual cells of an adherent bladder cancer 
cell line (T24) utilizing the Single-probe quantitative single cell mass spectrometry 
(qSCMS) method previously published in our lab (Chapter 4, 5). Analysis was performed 
following a 1-h incubation of gemcitabine at either 0.1, 1, or 10 µM (Figure 6-2, Table 6-
1, Figure B3). For method validation, 1-µM gemcitabine-treated T24 cells were 
trypsinized, washed with PBS, and analyzed using the ICMP. The amount of gemcitabine 
calculated from both methods was not significantly different (P > 0.05), verifying the 
Single-probe/ICMP method for quantification of non-adherent cells. 
 
Table 6-1. The concentrations of individual cells at the provided treatments using the 
averaged cell volume of K562 cells (Relative) (n > 20) and the measured volumes 
(Absolute) (n > 20) 
Treatment 
Concentration 
Relative Concentration Absolute Concentration 
0.1 µM 14.2  9.0 µM 10.9  7.1 µM 
1 µM 17.4  10.1 µM 17.9  11.9 µM 





 An advantage of the ICMP is that it allows for the analysis of a variety of cell types 
with minimal interferences from complex sampling matrices. The ICMP, consisting of an 
inverted microscope, two cell manipulation systems, a microinjector, a glass cell-selection 
probe, and a Single-probe, is capable of distinguishing cell types, morphologies, and 
sizes (Figure 6-1). The Single-probe/ICMP was further expanded to calculate the 
absolute concentration of gemcitabine from non-adherent chronic myeloid leukemia cells 
(K562) by measuring the diameter of each cell.90 K562 cells were treated under the same 
conditions as the adherent T24 cells. The absolute concentration of gemcitabine was 
compared with the relative  concentrations achieved using the average volume of K562 
cells (2.6 pL) (Table 6-2).131 There was no statistical difference between the 
concentrations calculated or the deviation within each data set between the two methods. 
Future work can be done using statistical analysis to determine how absolute 
concentrations correlate with cell size compared to the number of moles taken up. 
 
Figure 6-2. Moles (x10-18) of gemcitabine calculated inside individual cells. (a) Adherent 






Table 6-2. Moles (x10-18) of gemcitabine calculated inside individual T24 and K562 
cells. (n>30 for each treatment) 
Treatment Concentration T24 (Attomole) K562 (Attomole) 
0.1 µM 13.9  10.6 41.3  23.5 
1 µM 27.0  22.6 46.7  28.2 
10 µM 42.8  37.7 72.0  59.5 
 
 
  The amount of gemcitabine inside K562 cells followed a similar trend to T24 cells 
(Figure 6-2, Figure B3). There was an increase in intracellular gemcitabine quantification 
upon an increase in treatment condition and the 10-µM treatment also resulted in a 
significant increase in intracellular gemcitabine compared to 1 and 0.1 µM treatments. 
Additionally, the deviation of intracellular moles quantified within a treatment condition 
also increased with increasing treatment concentrations: the 10 µM treatment resulted in 









Figure 6-3. Mass spectrum of gemcitabine and 1-µM 15N3-gemcitabine from an individual 
cell isolated from the urine of a bladder cancer patient 1 h after a 1000 mg/m2 infusion of 
gemcitabine. 
 
 After the method was validated in vitro, the Single-probe/ICMP method for qSCMS 
was expanded to include the analysis of single cells isolated from the urine of bladder 
cancer patients (n=4). An initial qualitative analysis was performed on two patients who 
served as a control and were not subjected to gemcitabine chemotherapy. 
Phosphatidylcholines were qualitatively detected in single cells isolated from the urine of 
the bladder cancer patients (Figure B4), validating the capability of detecting small 






Figure 6-4. Experimental view of cells. (a) K562 cells and (b) Patient-derived cells. 
 
 
Following the qualitative analysis, gemcitabine quantification inside single cells 
was performed using the ICMP setup on two patients who underwent gemcitabine 
chemotherapy (1000 mg/m2 gemcitabine/treatment). Urine was collected from 
chemotherapy patients 1-h post-infusion (Figures 6-3 and 6-4, Figures B5-B7). 
Gemcitabine identification was validated through MS/MS analysis from a single patient-
isolated cell and standard solution (Figure B6). Gemcitabine was quantified from the 
patients who underwent chemotherapy but was not present in cells from the control group 
(Figure 6-3, Figure B5). The amount of drug calculated from gemcitabine patient 1 is 
significantly higher than patient 2, suggesting the regimen is more effective for patient 1 
(Table 6-3). There also seems to be a general trend that the amount of gemcitabine is 
increasing with increasing round of chemotherapy, suggesting that gemcitabine is 
accumulating between treatments. 
     The urine of gemcitabine-exposed patients was also tested by spiking the sample with 




of 1,490  470 µM and patient 2 had a concentration of 585  159 µM, which shows a 
relatively large amount of the anti-cancer compound being excreted through the urine 
within an hour after infusion. Additionally, the urine and the isolated cells also showed the 
non-active metabolite of gemcitabine, 2',2'-difluorodeoxyuridine (dFdU) (m/z 265.0621) 
(Figure 6-3), which could be quantified in the future to further determine efficacy of the 
drug treatment. 
6.4 Conclusion 
     In summary, we have developed a method for the quantification of the 
chemotherapeutic agent, gemcitabine, from single cells isolated from the in vitro adherent 
(T24) and non-adherent (K562) cell line models and, ultimately, from in vivo clinically 
isolated cells from bladder cancer patients. Furthermore, this technique can be applied 
for the metabolomic analysis of individual clinical cells, detecting significantly modified 
molecules between two populations of cells (i.e. healthy vs. cancerous). 
 
Table 6-3. Gemcitabine quantification from single isolated cells from two bladder cancer 
patients undergoing gemcitabine chemotherapy.  
Infusion Patient 1 (Attomoles)  Patient 2 (Attomoles)  
1 - 45.8  39.4 
2 473  187.7 79.4  50.9 
3 - - 






Further clinical studies are currently being set up to assess the therapeutically-
relevant levels of gemcitabine within the cell to apply this technique for personalized 
chemotherapeutic drug monitoring. Single-cell quantification of drug compounds isolated 
from non-invasive patient samples is a major advancement for the bioanalytical 
community and expanding this technology to include metabolites could improve 
personalized health care in the future, especially with regards to chemotherapeutic 
agents. 
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Chapter 7 :  Conclusions and Future Directions of Quantitative 
Single Cell Mass Spectrometry using the Single-probe Mass 
Spectrometry Technique 
 
7.1 Summary of Work 
 In this work, we expanded the versatility of the Single-probe mass spectrometry 
technique. First, an integrated cell manipulation platform was built. This platform consists 
of an inverted microscope to monitor cell selection, two Eppendorf cell manipulation 
systems to control the spatial movements of each of the probes, a ThermoPlate to mimic 
the cells’ native environment, a glass cell-selection device, and a Single-probe. This setup 
was then utilized for the detection of lipids from untreated cells, the detection of 
compounds from drug-treated cells, and untargeted analysis of cells from both drug-
treated and control (untreated) groups. Then, the Single-probe mass spectrometry 
technique was adapted for quantitative analysis of drug compounds from adherent cell 
lines. First, quantitative single cell mass spectrometry was validated by comparing the 
amount of drug compound from single cell analysis to the traditional method of LCMS 
analysis of cell lysate samples. Then, quantitative analysis was used to explore the 
kinetics of OSW-1 inside different cell lines. Finally, quantitative analysis was expanded 
to include the analysis of patient-derived cell samples.  
7.2 Implications of Work and Future Directions 
 The work presented in this manuscript has the potential to revolutionize 
personalized chemotherapeutic regimens for a variety of cancers. Since the tip of the 




any type of cell, adherent or non-adherent, as long as the cell is at least 5 µm in diameter. 
This method can also be applied to other disease states, since it is capable of providing 
information about cellular metabolites, both qualitatively and quantitatively, in a near-
native environment. The ambient conditions with minimal (or even no sample preparation 
for qualitative experiments using the ICMP/Singe-probe setup) can enhance our 
understanding of cellular processes. Since the “-omics” techniques are becoming popular, 
this method can be expanded to include peptidomics, metabolomics, lipidomics, etc.  
 There are a few studies that could be done to strengthen this technique in the 
future. First, the integration of a miniaturized plasma device or coupling the Singe-probe 
mass spectrometry method with inductively-coupled plasma (ICP) MS would allow for the 
analysis of compounds like cisplatin, a common chemotherapeutic drug, that cannot be 
easily quantified through this technique since its mechanism of action includes binding to 
DNA. Second, drugs could be studied as part of “co-treatments.” For example, cisplatin 
and gemcitabine are often used together as part of one chemotherapy regimen. Using 
multiple drugs to treat cell lines could be used to expand our knowledge of drug-drug 
interactions. Third, more patient samples can be analyzed. These samples can be broken 
down into analysis of cell type (i.e. cancer, healthy, red blood cell, etc.) or metabolites 
can be quantified to determine drug efficacy and better evaluate the course of 
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Figure A1. MS/MS verification of lipids with 10-40 manufacturer’s unit energy at: (a) m/z 
754.5 (b) m/z 780.5 (c) m/z 782.5 (d) m/z 784.5 (e) m/z 804.5 (f) m/z 808.5 (g) m/z 









Figure A2. MS/MS verification of lipids with 10-40 manufacturer’s unit energy at: (a) m/z 










B.1.1. Cell Cytotoxicity Assay.  
T24 cell lines were grown in McCoy’s medium supplemented with 10% synthetic 
FBS and 1% penicillin-streptomycin. All cells were maintained in an incubator at 37°C 
under 5% CO2, and they were passaged around 75% confluency. Cells (5000 cells/well) 
were plated into 96-well plates in 75 μL of medium. After 24 h, a time-zero plate was 
produced by adding 25 μL of medium and 20 μL of CellTiter-Blue (Promega) to the 
wells and then incubating the plates at 37 °C for 90 min. Fluorescence (560 nm 
excitation; 590 nm emission) was detected using a Tecan Infinite M200 to establish cell 
viability at time of dosing. Then, compounds were serially diluted in medium and 
delivered to the cells as 4x solutions in 25 μL of medium. After 48 h, CellTiter-Blue was 
added, and the fluorescence was recorded as described above. Growth relative to 
untreated cells was calculated, and this data was fitted to a four-parameter dose-
response curve using GraphPad Prism 8. 
 
B.1.2. Isotopically-Labeled Gemcitabine.  
Stable-isotopically labeled gemcitabine was accessed through a short sequence 
of reactions following the synthetic route that scientists at Eli Lily published in 1991.188 
The starting material 3,5-di-O-benzoate-2-deoxy-2,2-difluoro-D-ribofuranose 4.3 
(Scheme B1) was purchased commercially as a mixture of both anomers. The 
hemiacetal mixture was then activated as glycosyl donor by conversion of the free 




was prepared from commercially available 2-13C, 1,3-15N2 cytosine 4.5 (Scheme 35). 
Glycosyl acceptor 4.6 was prepared in situ from heating the mixture of cytosine 4.5 and 
hexamethyldisilane to reflux in presence of ammonium sulfate for 45 minutes. Utilizing 
the Vorbrueggen glycosylation method, the mesylated glycosyl donor 4.4 was reacted 
with silylated glycosyl acceptor 4.6 and trimethylsilyl trifluoromethanesulfonate as the 
activator in refluxing 1,2-dichloroethane for 48 hours. This reaction produced a mixture 
of protected isotopically labeled gemcitabine 4.7 (76% yield). The glycosylation reaction 
was presumed to proceed through an SN1 pathway involving an oxonium ion 
intermediate, which resulted in a mixture of nucleoside anomers with the ratio of α : β 
being 1.3 : 1 as measured through 1H NMR. 
Treating the mixture 4.7 with ammonia in anhydrous methanol effectively 
removed both benzoyl protecting groups. The anomeric mixture of deprotected 
nucleoside were successfully separated through semi-preparative reverse-phase HPLC 
to afford desired β-anomer (4.8 in 34% yield) and α-anomer (4.9 in 4.0% yield). The 
desired β-nucleoside 4.8 was then converted to the hydrochloride salt of gemcitabine 
4.10 in the presence of equimolar HCl in isopropanol. The molecular weight of the 
stable-isotopically labeled gemcitabine 4.10 was confirmed through high resolution 
mass spectrometry. 
 
B.1.3. Compound Data. 
Compound 4.4 (Scheme S1) was synthesized as previously described.189 To a 
solution of 2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate (200.0 mg, 0.529 mmol) 




followed by methanesulfonyl chloride (49 µL, 0.634 mmol). The reaction mixture was 
stirred at RT for 4h15m, when it was completed base on TLC analysis. The reaction 
mixture was diluted with DCM (20 mL), washed with 1N HCl (15 mL), 5% NaHCO3 
solution (15 mL), DI H2O (15 mL), and brine. The organic phase was dried over Na2SO4 
and filtered. The solvent was removed in vacuo to afford mixture of products (α:β = 
1.3:1) as a sticky yellow gel (200 mg, 82% yield). Products # was used in the next step 
without further purification. 1H NMR (400 MHz, Chloroform-d) δ 8.07 (dt, J = 8.5, 1.5 Hz, 
5H), 8.05 – 8.02 (m, 2H), 7.66 – 7.61 (m, 2H), 7.58 (td, J = 7.5, 1.4 Hz, 2H), 7.46 (dtd, J 
= 15.6, 7.7, 2.4 Hz, 9H), 6.13 (d, J = 6.3 Hz, 1H), 6.03 (d, J = 6.5 Hz, 0H), 5.93 (dd, J = 
15.0, 6.8 Hz, 1H), 5.57 (dd, J = 16.4, 4.3 Hz, 1H), 4.85 (q, J = 4.1 Hz, 1H), 4.79 – 4.70 
(m, 2H), 4.70 – 4.57 (m, 3H), 3.17 (s, 3H), 3.02 (s, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 166.01, 165.92, 165.09, 164.95, 134.35, 134.29, 133.74, 133.60, 
130.26, 130.19, 129.86, 129.23, 129.16, 128.85, 128.82, 128.79, 128.64, 128.14, 
127.98, 123.49, 123.13, 121.01, 120.74, 120.61, 120.45, 118.26, 117.93, 99.99, 99.74, 
99.52, 99.28, 99.21, 98.96, 98.79, 98.54, 82.83, 82.80, 82.77, 79.84, 79.76, 71.34, 
71.17, 70.98, 70.81, 69.75, 69.60, 69.49, 69.34, 63.06, 62.55, 40.42, 40.30.  
Compounds 4.7 were synthesized with procedure adapted from Chou et al.189 A 
suspension of isotopically labeled cytosine 4.5 (25.0 mg, 0.219 mmol), ammonium 
sulfate (1.2 mg, 0.009 mmol) in hexamethyldisilazane (300 µL, 1.4 mmol) was heated 
under reflux (130°C) for 45 minutes. The reaction mixture was then cooled to RT. Under 
N2 atmosphere, to this reaction mixture was added 1,2-dichloroethane (0.75 mL, 0.3 M) 
and trimethylsilyl trifluoromethanesulfonate (40 µL, 0.144 mmol). The clear, colorless 




(66 mg, 0.144 mmol, dissolved in 0.66 mL 1,2-dichloroethane). The reaction mixture 
was heated under reflux (90°C). The reaction progress was monitored by TLC (5% 
MeOH/CHCl3, UV). 1,2-DCE was added periodically to keep the same reaction 
concentration. After 72 hours, the reaction was completed based on TLC analysis. The 
reaction mixture was cooled to RT, the solvent was removed in vacuo to afford a thick 
gel, which was dissolved in EtOAc (40 mL), washed with DI H2O (5 mL x 3), 5% 
NaHCO3 solution (5 mL). The organic phased was dried over Na2SO4 and filtered. The 
solvent was removed in vacuo to afford crude mixture (64.8 mg), which was purified 
through silica gel column chromatography (eluted with MeOH/CHCl3 gradient, 2% to 
10% MeOH) to afford desired products 5 as a white powder (52.7 mg, 76% yield). 1H 
NMR (500 MHz, Chloroform-d) δ 8.10 – 8.03 (m, 6H), 8.03 – 7.99 (m, 2H), 7.67 – 7.56 
(m, 4H), 7.51 – 7.41 (m, 10H), 6.68 (t, J = 7.0 Hz, 1H), 6.56 (bs, 1H), 5.83 (dd, J = 7.6, 
3.6 Hz, 1H), 5.78 (dt, J = 10.3, 5.2 Hz, 1H), 5.70 (dd, J = 7.6, 3.7 Hz, 1H), 5.64 (d, J = 
13.1 Hz, 1H), 4.86 – 4.75 (m, 2H), 4.68 (dd, J = 12.4, 4.6 Hz, 1H), 4.64 (d, J = 5.0 Hz, 
2H), 4.55 (td, J = 4.7, 3.3 Hz, 1H). 
Compounds 4.8 and 4.9 were synthesized with procedure adapted from Chou et 
al.189To a suspension of 4.7 (47.6 mg, 0.10 mmol) in anhydrous MeOH (2 mL) at RT 
was added NH3 solution in MeOH (100 µL, 7M solution). The reaction mixture was 
stirred at RT and the reaction progress was monitored by TLC (10% MeOH/CHCl3, UV). 
The reaction was completed after 16h by TLC. The solvent was removed in vacuo to 
afford an oily residue, which was resuspended in DI H2O (10 mL) and EtOAc (5 mL). 
The aqueous phase was extracted with EtOAc (5 mL) while the organic phase was 




to afford crude product as a clear gel (25 mg, 94%). The crude mixture was purified 
through LCMS (C18 column, condition) to afford 4.9 (α-anomer-10.5 mg, 39.5%) and 
4.8 (β-anomer-9.0 mg, 33.9%). 
Compounds 4.10 were synthesized with procedure adapted from Chou et al.189 
4.8 (9.0 mg) was dissolved in DI H2O (0.5 mL) and isopropanol (0.5 mL), then HCl 
solution (6 µL of 6N solution) was added. The mixture was mixed for 5 minutes, then the 
solvent was removed in vacuo to afford 4.10 as a white solid (10.1 mg). 1H NMR (400 
MHz, Deuterium Oxide) δ 8.06 – 7.98 (m, 1H), 6.33 – 6.22 (m, 2H), 4.40 (td, J = 11.7, 
8.3 Hz, 1H), 4.18 – 4.09 (m, 1H), 4.04 (d, J = 12.3 Hz, 1H), 3.89 (dd, J = 13.1, 4.4 Hz, 
1H). 13C NMR (101 MHz, Deuterium Oxide) δ 160.58 (d, J = 14.2 Hz), 144.62 (d, J = 
12.6 Hz), 121.62 (t, J = 260.5 Hz), 96.44 (d, J = 3.7 Hz), 86.30 – 84.66 (m), 81.81 (d, J 
= 7.7 Hz), 71.46 – 68.07 (m), 60.12. 19F NMR (376 MHz, Deuterium Oxide) δ -116.75 
(dd, J = 13.0, 5.5 Hz), -117.39 (dd, J = 12.9, 5.4 Hz), -118.00, -118.64. IR and HRSM 


































Figure B2. Cytotoxicity assay of non-labeled gemcitabine (Gem) and stable-isotopically 



























Figure B3. Mass spectrum of gemcitabine and 15N3-gemcitabine after gemcitabine 
treatment (10 µM, 1 h). (a) Spectrum from a single T24 cell and (b) spectrum from a 












Figure B4. Mass spectrum of a single cell isolated from a bladder cancer patient 
















Figure B6:  MS/MS spectra of Gemcitabine. A) MS/MS spectra of gemcitabine 
analyzed from a single cell isolated from bladder cancer patient 1. B) MS/MS of 
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Figure B7: Scatter plot depicting single cell quantification of gemcitabine from bladder 







Figure B8: Spectrum of Gemcitabine depicting the limit of quantification (LOQ) utilizing 
the single probe in a 5nM gemcitabine solution in acetonitrile.  
 
